{"content":"<li class=\"n-box-item date-title\" data-end=\"1492574399\" data-start=\"1492488000\" data-txt=\"Monday, December 23, 2019\">Tuesday, April 18, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3257773\" data-ts=\"1492558401\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOLD\" target=\"_blank\">BOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257773-audentes-prices-stock-offering-14_50-shares-off-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Audentes prices stock offering at $14.50; shares off 1% after hours</a></h4><ul><li>Audentes Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/BOLD' title='Audentes Therapeutics'>BOLD</a>) <a href=\"https://seekingalpha.com/pr/16802656-audentes-therapeutics-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of 5.2M common shares at $14.50 per share. Underwriters over-allotment is an additional 780K shares. Closing date is April 24.</li><li>Today's close was $15.19. Shares are down&nbsp;<font color='red'>1%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257773\" data-linked=\"Audentes prices stock offering at $14.50; shares off 1% after hours\" data-tweet=\"$BOLD - Audentes prices stock offering at $14.50; shares off 1% after hours https://seekingalpha.com/news/3257773-audentes-prices-stock-offering-14_50-shares-off-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3257773-audentes-prices-stock-offering-14_50-shares-off-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257770\" data-ts=\"1492556661\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257770-main-suppliers-hold-places-in-samsung-galaxy-s8-phone\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Main suppliers hold places in Samsung Galaxy S8 phone</a></h4><ul>   <li>A teardown of the new Galaxy S8 flagship phone (<a href=\"http://seekingalpha.com/symbol/SSNLF\" target=\"_blank\">SSNLF</a> <font color='green'>+23.3%</font>) shows some <a href=\"http://blogs.barrons.com/techtraderdaily/2017/04/18/qualcomm-skyworks-broadcom-hold-onto-top-spots-in-samsung-galaxy-s8/\" target=\"_blank\">strong similarity</a> to the fire-plagued Note 7 device from last year -- and also that key suppliers are still holding their spots in Samsung's lead device.</li>    <li>The <a href=\"http://ifixit.org/blog/9040/samsung-galaxy-s8-teardown/\" target=\"_blank\">iFixit story</a> notes basic architecture is unchanged and many parts are \"virtually identical\"; the design around the battery is even \"very, very similar\" to the Note 7.</li>    <li>The phone's got a Snapdragon processor (<a href=\"http://seekingalpha.com/symbol/QCOM\" target=\"_blank\">QCOM</a> <font color='red'>-0.4%</font>), and wins on RF chips by Broadcom (<a href=\"http://seekingalpha.com/symbol/AVGO\" target=\"_blank\">AVGO</a> <font color='red'>-0.4%</font>) and Skyworks (<a href=\"http://seekingalpha.com/symbol/SWKS\" target=\"_blank\">SWKS</a> <font color='green'>+0.3%</font>) were \"to be expected,\" says Raymond James' Simon Leopold, considering the teardown was of an Asian version (rather than a North American version that is likely to have a bigger presence from Qorvo (<a href=\"http://seekingalpha.com/symbol/QRVO\" target=\"_blank\">QRVO</a> <font color='green'>+0.7%</font>)). NXP (<a href=\"http://seekingalpha.com/symbol/NXP\" target=\"_blank\">NXP</a> <font color='green'>+0.1%</font>) held its role as the NFC controller chip maker.</li>    <li>After hours: <a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a> <font color='green'>+0.2%</font>; <a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Limited'>AVGO</a> flat; <a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a> flat; <a href='https://seekingalpha.com/symbol/QRVO' title='Qorvo, Inc'>QRVO</a> <font color='red'>-0.4%</font>; <a href='https://seekingalpha.com/symbol/NXP' title='Nuveen Select Tax-Free Income Portfolio'>NXP</a> flat.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257770\" data-linked=\"Main suppliers hold places in Samsung Galaxy S8 phone\" data-tweet=\"$QCOM $QCOM $AVGO - Main suppliers hold places in Samsung Galaxy S8 phone https://seekingalpha.com/news/3257770-main-suppliers-hold-places-in-samsung-galaxy-s8-phone?source=tweet\" data-url=\"https://seekingalpha.com/news/3257770-main-suppliers-hold-places-in-samsung-galaxy-s8-phone\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257766\" data-ts=\"1492554933\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOIVF\" target=\"_blank\">BOIVF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257766-italy-ruling-vivendi-cant-keep-stakes-in-ti-mediaset\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Italy ruling: Vivendi can&#39;t keep stakes in both TI, Mediaset</a></h4><ul>   <li>Acquisitive Vivendi (<a href=\"http://seekingalpha.com/symbol/VIVHY\" target=\"_blank\">VIVHY</a> <font color='red'>-1.8%</font>) <a href=\"https://www.wsj.com/articles/italian-regulators-rule-vivendi-cant-keep-big-stakes-in-both-mediaset-telecom-italia-1492549654?mod=yahoo_hs&amp;yptr=yahoo\" target=\"_blank\">can't maintain its big stakes in both</a> Telecom Italia (<a href=\"http://seekingalpha.com/symbol/TI\" target=\"_blank\">TI</a> <font color='red'>-2.6%</font>) and Mediaset (<a href=\"http://seekingalpha.com/symbol/MDIUY\" target=\"_blank\">MDIUY</a> <font color='red'>-2.7%</font>), Italy's communications regulator says, following assertive moves from the French telecom to build a telecom/media beachhead in Italy.</li>    <li>Moves by Vivendi mogul Vincent Bollore (<a href='https://seekingalpha.com/symbol/BOIVF' title='BOLLORE INVESTISSEMNT ORD'>OTCPK:BOIVF</a>) to build the stakes violates antitrust laws that restrict shares in both telecom and media markets in Italy, AGCOM said.</li>    <li>So Vivendi will have to choose and get rid of one of the stakes within a year, the regulator said, giving the company 60 days to submit a plan. Analysts think if his hand is forced, Bollore will choose to keep the TI stake.</li>    <li>Bollore took nearly a 30% stake in Mediaset last year, and slowly built a stake in Telecom Italia that's at 24%. Vivendi will appeal the decision, saying former Prime Minister Silvio Berlusconi exercises effective control over Mediaset.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257766\" data-linked=\"Italy ruling: Vivendi can&#39;t keep stakes in both TI, Mediaset\" data-tweet=\"$BOIVF $BOIVF $VIVHY - Italy ruling: Vivendi can&#39;t keep stakes in both TI, Mediaset https://seekingalpha.com/news/3257766-italy-ruling-vivendi-cant-keep-stakes-in-ti-mediaset?source=tweet\" data-url=\"https://seekingalpha.com/news/3257766-italy-ruling-vivendi-cant-keep-stakes-in-ti-mediaset\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257764\" data-ts=\"1492554068\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALPN\" target=\"_blank\">ALPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257764-nivalis-therapeutics-to-merge-alpine-immune-sciences\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nivalis Therapeutics to merge with Alpine Immune Sciences</a></h4><ul>     <li>Nivalis Therapeutics (NVLS)&nbsp;<font color='green'>+26.9%</font>&nbsp;AH after disclosing it will <a href=\"https://seekingalpha.com/filing/3507244\" target=\"_blank\">merge</a> with Alpine Immune Sciences in an all-stock deal.</li><li><a href=\"https://www.thestreet.com/story/14091921/1/former-dendreon-ceo-mitch-gold-returns-to-public-biotech-stage-with-cancer-immunotherapy-merger.html\" target=\"_blank\">Alpine will take over</a> what is essentially a non-operating  NVLS shell company following the January failure of  a cystic fibrosis drug clinical trial; once the merger is complete in Q3, the combined companies will take the Alpine Immune Sciences name and focus on its pipeline of protein-based immunotherapy drugs.</li><li>Alpine's public market debut marks a return of  controversial former Dendreon CEO Mitch Gold.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257764\" data-linked=\"Nivalis Therapeutics to merge with Alpine Immune Sciences\" data-tweet=\"$ALPN - Nivalis Therapeutics to merge with Alpine Immune Sciences https://seekingalpha.com/news/3257764-nivalis-therapeutics-to-merge-alpine-immune-sciences?source=tweet\" data-url=\"https://seekingalpha.com/news/3257764-nivalis-therapeutics-to-merge-alpine-immune-sciences\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257763\" data-ts=\"1492553580\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LRCX\" target=\"_blank\">LRCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257763-lam-researchplus-4_8-after-earnings-beat-upbeat-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lam Research +4.8% after earnings beat, upbeat guidance</a></h4><ul>   <li>Lam Research (NASDAQ:<a href='https://seekingalpha.com/symbol/LRCX' title='Lam Research Corporation'>LRCX</a>) is among tech's top postmarket gainers, <font color='green'>up 4.8%</font> after hours after it beat consensus on top and bottom lines in its <a href=\"https://seekingalpha.com/news/3257709-lam-research-beats-0_25-beats-revenue\" target=\"_blank\">Q1 earnings</a>.</li>    <li>Revenues rose 64% (up 14% Q/Q) and shipments increased to $2.41B (up 25% Q/Q). Gross margin (non-GAAP) fell 30 basis points and operating margin increased 90 basis points.</li>    <li>Revenue distribution by region: Korea, 34%; Taiwan, 28%; China, 11%; Japan, 11%; U.S., 9%; Europe, 4%; Southeast Asia, 3%.</li>    <li>Cash and equivalents, short-term investments, and restricted cash and investments were steady at $6.1B. Cash from operations was $423M.</li>    <li>For the June quarter, it's guiding to shipments of $2.4B-$2.6B and revenues of $2.2B-$2.4B (above consensus for $2.19B), along with EPS of $2.88-$3.12 (above expectations for $2.66). It sees gross margin at 45-47% and operating margin at 26-28%.</li>    <li><a href=\"https://seekingalpha.com/pr/16802466-lam-research-corporation-reports-financial-results-quarter-ended-march-26-2017\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3257763\" data-linked=\"Lam Research +4.8% after earnings beat, upbeat guidance\" data-tweet=\"$LRCX - Lam Research +4.8% after earnings beat, upbeat guidance https://seekingalpha.com/news/3257763-lam-researchplus-4_8-after-earnings-beat-upbeat-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3257763-lam-researchplus-4_8-after-earnings-beat-upbeat-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257761\" data-ts=\"1492552216\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RARE\" target=\"_blank\">RARE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257761-ultragenyx-pharmaplus-20-on-positive-results-for-hypophosphatemia-drug-test\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ultragenyx Pharma +20% on positive results for hypophosphatemia drug test</a></h4><ul>     <li>Ultragenyx Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/RARE' title='Ultragenyx Pharmaceutical Inc.'>RARE</a>)&nbsp;<font color='green'>+19.8%</font>&nbsp;AH on news that its burosumab  drug to treat x-linked hypophosphatemia, a genetic kidney disorder, <a href=\"https://seekingalpha.com/pr/16802434-ultragenyx-kyowa-hakko-kirin-kyowa-kirin-international-announce-positive-24-week-data-adult\" target=\"_blank\">met its primary endpoint</a> in a phase 3 study.</li>     <li>RARE says patients treated with the drug showed a statistically significant improvement in serum phosphorus levels, with 94% of patients achieving normal levels vs. 8% on placebo.</li><li>The study was jointly conducted with Japan's Kyowa Hakko Kirin.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257761\" data-linked=\"Ultragenyx Pharma +20% on positive results for hypophosphatemia drug test\" data-tweet=\"$RARE - Ultragenyx Pharma +20% on positive results for hypophosphatemia drug test https://seekingalpha.com/news/3257761-ultragenyx-pharmaplus-20-on-positive-results-for-hypophosphatemia-drug-test?source=tweet\" data-url=\"https://seekingalpha.com/news/3257761-ultragenyx-pharmaplus-20-on-positive-results-for-hypophosphatemia-drug-test\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257759\" data-ts=\"1492551425\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257759-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> NVLS <font color='green'>+30.3%</font>. <a href='https://seekingalpha.com/symbol/RARE' title='Ultragenyx Pharmaceutical Inc.'>RARE</a> <font color='green'>+19.8%</font>. <a href='https://seekingalpha.com/symbol/CAMP' title='CalAmp Corp.'>CAMP</a> <font color='green'>+5.4%</font>. <a href='https://seekingalpha.com/symbol/LRCX' title='Lam Research Corporation'>LRCX</a> <font color='green'>+4.4%</font>. <a href='https://seekingalpha.com/symbol/ISRG' title='Intuitive Surgical, Inc.'>ISRG</a> <font color='green'>+3.5%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/DSX' title='Diana Shipping, Inc.'>DSX</a> <font color='red'>-7.2%</font>. <a href='https://seekingalpha.com/symbol/LTXB' title='LegacyTexas Financial Group Inc.'>LTXB</a> <font color='red'>-6.9%</font>. <a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a> <font color='red'>-4.2%</font>. <a href='https://seekingalpha.com/symbol/MC' title='Moelis & Company'>MC</a> <font color='red'>-4.0%</font>. <a href='https://seekingalpha.com/symbol/GTN' title='Gray Television, Inc.'>GTN</a> <font color='red'>-2.7%.</font></li> </ul><div class=\"tiny-share-widget\" data-id=\"3257759\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$ALPN $RARE $CAMP - After Hours Gainers / Losers https://seekingalpha.com/news/3257759-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3257759-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257749\" data-ts=\"1492549130\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLG\" target=\"_blank\">PLG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257749-platinum-group-metals-in-20m-bought-deal-financing-1_30-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Platinum Group Metals in $20M bought deal financing at $1.30/share</a></h4><ul>     <li>Platinum Group Metals (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLG' title='Platinum Group Metals Ltd'>PLG</a>) <font color='red'>-10.9%</font>&nbsp;AH after announcing a <a href=\"https://seekingalpha.com/pr/16802510-platinum-group-metals-announces-us-20-million-bought-deal-financing\" target=\"_blank\">$20M bought deal financing</a> with BMO&nbsp;Capital for 15.39M common shares at $1.30 each.</li>     <li>PLG grants BMO a 30-day option to purchase up to an additional 15% of the offering to cover over-allotments.</li><li>PLG plans to use the proceeds for underground development  and production ramp-up of the Maseve mine; for working capital  during start-up; for repaying $2.5M of a prior advance under its credit agreement with a  syndicate of lenders; and for general corporate purposes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257749\" data-linked=\"Platinum Group Metals in $20M bought deal financing at $1.30/share\" data-tweet=\"$PLG - Platinum Group Metals in $20M bought deal financing at $1.30/share https://seekingalpha.com/news/3257749-platinum-group-metals-in-20m-bought-deal-financing-1_30-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3257749-platinum-group-metals-in-20m-bought-deal-financing-1_30-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257746\" data-ts=\"1492549065\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAMP\" target=\"_blank\">CAMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257746-calampplus-5_4-focused-business-boosts-revenues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CalAmp +5.4% as more focused business boosts revenues</a></h4><ul>   <li>CalAmp (NASDAQ:<a href='https://seekingalpha.com/symbol/CAMP' title='CalAmp Corp.'>CAMP</a>) is <font color='green'>up 5.4%</font> in building postmarket trading after edging analyst expectations with its <a href=\"https://seekingalpha.com/news/3257707-calamp-beats-0_01-beats-revenue\" target=\"_blank\">Q4 earnings report</a></li>    <li>Revenue in its Wireless DataCom segment rose 46% to $86.1M, and the Satellite business (which ended operations last Aug. 31) had $11.9M in revenue in the year-ago quarter. LoJack contributed $27.8M to revenues.</li>    <li>Gross profit in the remaining business rose to $35.8M, though, from $23.9M.</li>    <li>Adjusted EBITDA was $12.8M vs. a year-ago $13.7M, missing an expected $12.99M.</li>    <li>It's guiding to Q1 revenue of $84M-$90M (vs. consensus for $88.2M), non-GAAP EPS of $0.24-$0.32 (vs. $0.28 expected) and EBITDA of $11M-$14M (vs. $14M consensus).</li>    <li><a href=\"https://seekingalpha.com/pr/16802455-calamp-reports-fourth-quarter-fiscal-year-2017-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3257746\" data-linked=\"CalAmp +5.4% as more focused business boosts revenues\" data-tweet=\"$CAMP - CalAmp +5.4% as more focused business boosts revenues https://seekingalpha.com/news/3257746-calampplus-5_4-focused-business-boosts-revenues?source=tweet\" data-url=\"https://seekingalpha.com/news/3257746-calampplus-5_4-focused-business-boosts-revenues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257742\" data-ts=\"1492548656\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAVI\" target=\"_blank\">NAVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257742-navient-misses-0_06-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navient misses by $0.06, misses on revenue</a></h4><ul><li>Navient (NASDAQ:<a href='https://seekingalpha.com/symbol/NAVI' title='Navient Corp'>NAVI</a>): Q1 EPS of $0.36 <font color='red'>misses by $0.06</font>.</li><li>Revenue of $340M (-30.0% Y/Y) <font color='red'>misses by $10.57M</font>.</li><li>Shares <font color='green'>+2.6%</font>.</li><li><a href=\"https://www.google.com/finance?authuser=0&amp;q=NASDAQ%3ANAVI&amp;hl=en&amp;ei=Cnr2WNi-J83ouAS8iZww\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3257742\" data-linked=\"Navient misses by $0.06, misses on revenue\" data-tweet=\"$NAVI - Navient misses by $0.06, misses on revenue https://seekingalpha.com/news/3257742-navient-misses-0_06-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3257742-navient-misses-0_06-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257725\" data-ts=\"1492547410\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DSX\" target=\"_blank\">DSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257725-diana-shipping-down-7-on-capital-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Diana Shipping down 7% on capital raise</a></h4><ul><li>The company aims <a href=\"https://seekingalpha.com/pr/16802478-diana-shipping-inc-announces-public-offering-common-shares\" target=\"_blank\">to sell $70M worth of common stock</a>, with an underwriter greenshoe for up to another $10.5M of shares.</li><li>Diana's (NYSE:<a href='https://seekingalpha.com/symbol/DSX' title='Diana Shipping, Inc.'>DSX</a>) Chairman and CEO, other executive officers, and certain board members have agreed to take down about $20M of the offering.</li><li>The proceeds are to be used for the purchase of additional dry bulk vessels, including a number that have already been agreed upon.</li><li>Shares<font color='red'> -7.25%&nbsp;</font>after hours to $4.74.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257725\" data-linked=\"Diana Shipping down 7% on capital raise\" data-tweet=\"$DSX - Diana Shipping down 7% on capital raise https://seekingalpha.com/news/3257725-diana-shipping-down-7-on-capital-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3257725-diana-shipping-down-7-on-capital-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257721\" data-ts=\"1492547139\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ISRG\" target=\"_blank\">ISRG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257721-intuitive-surgical-q1-revenues-up-13-eps-up-32-shares-up-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intuitive Surgical Q1 revenues up 13%; EPS up 32%; shares up 4% after hours</a></h4><ul><li>Intuitive Surgical (NASDAQ:<a href='https://seekingalpha.com/symbol/ISRG' title='Intuitive Surgical, Inc.'>ISRG</a>) <a href=\"https://seekingalpha.com/pr/16802467-intuitive-surgical-announces-first-quarter-earnings\" target=\"_blank\">Q1 results</a> ($M): Total Revenues: 674.2 (+13.4%); Instruments and Accessories: 380.8 (+18.2%); Systems: 153.2 (+3.6%); Services: 140.2 (+12.6%).</li><li>Net Income: 179.8 (+31.8%); Non-GAAP Net Income: 196.0 (+15.1%); EPS: 4.67 (+31.9%); Non-GAAP EPS: 5.09 (+15.2%).</li><li>Shipments of <em>da Vinci</em> systems: 133 (+20.9%).</li><li>Consensus view for Q2 is EPS of $4.97 on revenues of $731M.</li><li>Shares are up&nbsp;<font color='green'>4%</font>&nbsp;after hours on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257721\" data-linked=\"Intuitive Surgical Q1 revenues up 13%; EPS up 32%; shares up 4% after hours\" data-tweet=\"$ISRG - Intuitive Surgical Q1 revenues up 13%; EPS up 32%; shares up 4% after hours https://seekingalpha.com/news/3257721-intuitive-surgical-q1-revenues-up-13-eps-up-32-shares-up-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3257721-intuitive-surgical-q1-revenues-up-13-eps-up-32-shares-up-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257714\" data-ts=\"1492546705\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBM\" target=\"_blank\">IBM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257714-ibmminus-3_6-quarterly-revenue-drops-yet-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IBM -3.6% as quarterly revenue drops yet again</a></h4><ul>   <li><a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a> is <font color='red'>3.6% lower</font> in aftermarket trade after its <a href=\"https://seekingalpha.com/news/3257705-international-business-machines-beats-0_03-misses-revenue\" target=\"_blank\">Q1 revenues</a> marked the 20th straight quarter of Y/Y declines, and missed expectations significantly.</li>    <li>Revenues fell 2.8% to $18.16B vs. an expected $18.39B, though EPS of $2.38 beat the Street.</li>    <li>Strategic imperatives revenue was up 12% to $7.8B, the company notes, and it rose to 42% of revenue over the past 12 months ($33.6B).</li>    <li>Revenue by segment: Cognitive Solutions, $4.06B (up 2.1%); Global Business Services, $4.01B (down 3%); Technology Services and Cloud Platforms, $8.22B (down 2.5%); Systems, $1.4B (down 16.7%); Global Financing, $405M (down 1.2%).</li>    <li>The company reiterated its guidance for the full year, of operating (non-GAAP) EPS of at least $13.80 (vs. consensus for $13.78) -- adjusting for acquisition-related charges of $0.75/share and non-operating retirement-related items of $1.10/share.</li>    <li>Net cash from operations was $4B for the quarter ($1.9B excluding Global Financing receivables). Free cash flow was $1.1B.</li>    <li><a href=\"http://www.ibm.com/investor/events/earnings/1q17.html\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16802472-ibm-reports-2017-first-quarter-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3257714\" data-linked=\"IBM -3.6% as quarterly revenue drops yet again\" data-tweet=\"$IBM - IBM -3.6% as quarterly revenue drops yet again https://seekingalpha.com/news/3257714-ibmminus-3_6-quarterly-revenue-drops-yet-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3257714-ibmminus-3_6-quarterly-revenue-drops-yet-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257709\" data-ts=\"1492546098\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LRCX\" target=\"_blank\">LRCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257709-lam-research-beats-0_25-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lam Research beats by $0.25, beats on revenue</a></h4><ul><li>Lam Research (NASDAQ:<a href='https://seekingalpha.com/symbol/LRCX' title='Lam Research Corporation'>LRCX</a>): Q1 EPS of $2.80 <font color='green'>beats by $0.25</font>.</li><li>Revenue of $2.15B (+64.1% Y/Y) <font color='green'>beats by $20M</font>.</li><li>Shares <font color='green'>+1.2%</font>.</li><li><a href='https://seekingalpha.com/pr/16802466-lam-research-corporation-reports-financial-results-quarter-ended-march-26-2017'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3257709\" data-linked=\"Lam Research beats by $0.25, beats on revenue\" data-tweet=\"$LRCX - Lam Research beats by $0.25, beats on revenue https://seekingalpha.com/news/3257709-lam-research-beats-0_25-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3257709-lam-research-beats-0_25-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257699\" data-ts=\"1492545541\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSIX\" target=\"_blank\">PSIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257699-power-solutions-to-be-delisted-sharesminus-31\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Power Solutions to be delisted; shares -31%</a></h4><ul><li>Power Solutions International (<a href='https://seekingalpha.com/symbol/PSIX' title='Power Solutions International, Inc.'>OTCPK:PSIX</a> <font color='red'>-31%</font>) plunges in afternoon trading following reports that the stock will be <a href=\"https://twitter.com/EliteDayTraders/status/854409562266501123\" target=\"_blank\">delisted</a> from the Nasdaq, effective April 20.</li><li>PSIX had filed to delay its 10-K filing on March 17.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257699\" data-linked=\"Power Solutions to be delisted; shares -31%\" data-tweet=\"$PSIX - Power Solutions to be delisted; shares -31% https://seekingalpha.com/news/3257699-power-solutions-to-be-delisted-sharesminus-31?source=tweet\" data-url=\"https://seekingalpha.com/news/3257699-power-solutions-to-be-delisted-sharesminus-31\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257694\" data-ts=\"1492545256\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VZ\" target=\"_blank\">VZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257694-verizon-gets-lift-ceo-says-talk-merger-comcast-disney-others\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verizon gets lift as CEO says he&#39;d talk merger with Comcast, Disney, others</a></h4><ul>   <li>Verizon (NYSE:<a href='https://seekingalpha.com/symbol/VZ' title='Verizon Communications'>VZ</a>) is rising into the close, <font color='green'>up 1.3%</font>, as chief Lowell McAdam says he's open to talks about merger deals with any number of power players in media/telecom, including Comcast (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) and Disney (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>).</li>    <li>He'd discuss a merger if it would reset the company's course amid rapid change, he said.</li>    <li><a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a> is sparking a bit, <font color='green'>+0.4%</font>, and <a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a> has <font color='green'>spiked 0.8%</font>.</li>    <li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257694\" data-linked=\"Verizon gets lift as CEO says he&#39;d talk merger with Comcast, Disney, others\" data-tweet=\"$VZ $VZ $CMCSA - Verizon gets lift as CEO says he&#39;d talk merger with Comcast, Disney, others https://seekingalpha.com/news/3257694-verizon-gets-lift-ceo-says-talk-merger-comcast-disney-others?source=tweet\" data-url=\"https://seekingalpha.com/news/3257694-verizon-gets-lift-ceo-says-talk-merger-comcast-disney-others\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>61&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257692\" data-ts=\"1492544729\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALO\" target=\"_blank\">ALO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257692-timmins-gold-proposes-name-change-to-alio-gold\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Timmins Gold proposes name change to Alio Gold</a></h4><ul>     <li>Timmins Gold (TGD <font color='red'>-3.1%</font>) proposes to <a href=\"https://seekingalpha.com/filing/3506797\" target=\"_blank\">change its name</a> to Alio Gold at its upcoming annual shareholder meeting, saying the new name reflects the operational and  management changes made over the past year.</li><li>If approved, the company expects to begin trading on both the NYSE MKT and Toronto exchanges under the ALO ticker on May 16.</li><li>TGD points to potential near-term catalysts for Alio Gold, including a pre-feasibility study for its Ana Paula project and the plan for revitalizing the San  Francisco Mine.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257692\" data-linked=\"Timmins Gold proposes name change to Alio Gold\" data-tweet=\"$ALO - Timmins Gold proposes name change to Alio Gold https://seekingalpha.com/news/3257692-timmins-gold-proposes-name-change-to-alio-gold?source=tweet\" data-url=\"https://seekingalpha.com/news/3257692-timmins-gold-proposes-name-change-to-alio-gold\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257688\" data-ts=\"1492544567\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBYI\" target=\"_blank\">PBYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257688-truncated-ad-comm-review-bearish-for-pumas-neratinib-says-feuerstein-shares-down-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Truncated Ad Comm review bearish for Puma&#39;s neratinib says Feuerstein; shares down 8%</a></h4><ul><li>The FDA's Oncologic Drugs Advisory Committee is <a href=\"https://www.fda.gov/AdvisoryCommittees/Calendar/ucm553431.htm\" target=\"_blank\">scheduled to review </a>and discuss Puma Biotechnology's (<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='red'>-8%</font>) New Drug Application &#40;NDA&#41; seeking approval of neratinib for the adjuvant treatment of HER2-positive breast cancer on the morning of May 24. Bulls believe that the finish line is approaching while bears believe that the vote will be a clear thumbs down due to the drug's modest impact on disease-free survival coupled with its serious diarrhea side effect.</li><li>TheStreet's Adam Feuerstein <a href=\"https://www.thestreet.com/story/14091093/1/shortened-fda-advisory-panel-is-bad-omen-for-puma-bio-s-controversial-breast-cancer-drug.html\" target=\"_blank\">adds another perspective</a> on the issue. He says past history with half-day sessions bodes ill for a positive vote. Over the past five years, 67% (n=8/12) of short review sessions have ended poorly for the product candidates. The review team has spent the bulk of the time bashing the drug which takes much less time than reviewing and discussing positive data.</li><li>A recent example involved Clovis Oncology's lung cancer candidate rociletinib, the subject of a half-day review in April 2016, which received a 12-1 vote against accelerated approval.</li><li>Phase 3 results presented at a medical conference last December underscore the potential headwinds facing neratinib. 96.4% of treated patients experienced all-grade diarrhea, with almost 40% being grade 3 (severe) or higher.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257688\" data-linked=\"Truncated Ad Comm review bearish for Puma&#39;s neratinib says Feuerstein; shares down 8%\" data-tweet=\"$PBYI - Truncated Ad Comm review bearish for Puma&#39;s neratinib says Feuerstein; shares down 8% https://seekingalpha.com/news/3257688-truncated-ad-comm-review-bearish-for-pumas-neratinib-says-feuerstein-shares-down-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3257688-truncated-ad-comm-review-bearish-for-pumas-neratinib-says-feuerstein-shares-down-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257689\" data-ts=\"1492544002\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLST\" target=\"_blank\">NLST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257689-netlistplus-14-adopts-rights-deal-tied-to-sk-hynix-patent-case\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netlist +14%, adopts rights deal tied to SK Hynix patent case</a></h4><ul>   <li>Netlist (<a href='https://seekingalpha.com/symbol/NLST' title='Netlist, Inc.'>OTC:NLST</a>) is among today's top tech gainers, moving <font color='green'>up 14.2%</font> and touching its highest point since mid-November.</li>    <li>Volume is running more than five times recent daily average.</li>    <li>The company yesterday evening adopted a short-term <a href=\"https://seekingalpha.com/pr/16800845-netlist-adopts-short-term-stockholder-rights-agreement-initial-purchase-price-6_56-per-right\" target=\"_blank\">stockholder rights agreement</a> that grants preferred stock purchase rights to its shareholders -- an arrangement tied to an ongoing patent case against South Korea's SK Hynix.</li>    <li>The rights restrict any person or group from hitting a stake of 15% or more in beneficial ownership, strengthening the board's hand in case of a combination or takeover attempt.</li>    <li>The exercise price is $6.56 per right, equating to aggregate market value of outstanding securities of about $500M.</li>    <li>\"The purpose of this short-term rights agreement is to disconnect the Company's current market capitalization from any potential damages calculations and settlement negotiations that may develop in connection with the Company's patent infringement litigation against SK Hynix,\" says Chairman C.K. Hong.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257689\" data-linked=\"Netlist +14%, adopts rights deal tied to SK Hynix patent case\" data-tweet=\"$NLST - Netlist +14%, adopts rights deal tied to SK Hynix patent case https://seekingalpha.com/news/3257689-netlistplus-14-adopts-rights-deal-tied-to-sk-hynix-patent-case?source=tweet\" data-url=\"https://seekingalpha.com/news/3257689-netlistplus-14-adopts-rights-deal-tied-to-sk-hynix-patent-case\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257685\" data-ts=\"1492543444\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTU\" target=\"_blank\">BTU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257685-peabody-energy-too-cheap-after-two-week-slide-j-p-morgan-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Peabody Energy too cheap after two-week slide, J.P. Morgan analyst says</a></h4><ul>     <li>Peabody Energy (<a href='https://seekingalpha.com/symbol/BTU' title='Peabody Energy Corp.'>BTU</a> <font color='green'>+2.6%</font>) has lost nearly a quarter of its market cap since it emerged from bankruptcy and started trading on April 4, but J.P. Morgan analyst John Bridges contends that the stock's <a href=\"http://blogs.barrons.com/stockstowatchtoday/2017/04/18/peabody-energy-just-too-darn-cheap/?mod=BOL_hp_blog_stw\" target=\"_blank\">weakness looks overdone</a>.</li>     <li>Bridges believes coal must remain a key part of the U.S. energy mix for reliability reasons, agrees with BTU's optimism for growth in thermal coal sales into southeast Asia, and says \"published gas costs may not be telling the whole economic story.\"</li>     <li>Also, FBR analysts raise their BTU stock price target to $34, seeing the <a href=\"https://seekingalpha.com/news/3257621-south32-abandons-deal-buy-australian-coal-mine-peabody\" target=\"_blank\">failure</a> of the Metropolitan Coal sale as \"slightly positive\" for valuation given the current strength in met coal prices.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257685\" data-linked=\"Peabody Energy too cheap after two-week slide, J.P. Morgan analyst says\" data-tweet=\"$BTU - Peabody Energy too cheap after two-week slide, J.P. Morgan analyst says https://seekingalpha.com/news/3257685-peabody-energy-too-cheap-after-two-week-slide-j-p-morgan-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3257685-peabody-energy-too-cheap-after-two-week-slide-j-p-morgan-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257683\" data-ts=\"1492542739\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INVN\" target=\"_blank\">INVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257683-invensenseplus-3_2-on-clearances-for-tdk-buyout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">InvenSense +3.2% on clearances for TDK buyout</a></h4><ul>   <li>InvenSense (NYSE:<a href='https://seekingalpha.com/symbol/INVN' title='InvenSense'>INVN</a>) is <font color='green'>up 3.2%</font> today after announcing it's gotten <a href=\"https://seekingalpha.com/pr/16801814-invensense-receives-regulatory-clearances\" target=\"_blank\">regulatory clearances</a> for its $1.3B buyout by TDK (<a href='https://seekingalpha.com/symbol/TTDKY' title='TDK Corp. ADR'>OTCPK:TTDKY</a>).</li>    <li>The Hart-Scott-Rodino waiting period has expired and the Committee on Foreign Investment in the United States has OK'd the deal, InvenSense says.</li>    <li>It's set a special meeting for May 17 for stockholders to approve, and expects closing shortly thereafter.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257683\" data-linked=\"InvenSense +3.2% on clearances for TDK buyout\" data-tweet=\"$INVN $INVN $TTDKY - InvenSense +3.2% on clearances for TDK buyout https://seekingalpha.com/news/3257683-invensenseplus-3_2-on-clearances-for-tdk-buyout?source=tweet\" data-url=\"https://seekingalpha.com/news/3257683-invensenseplus-3_2-on-clearances-for-tdk-buyout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257682\" data-ts=\"1492542705\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDNA\" target=\"_blank\">CDNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257682-caredx-still-not-2016-annual-report-shares-ease-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CareDx still not there with 2016 annual report; shares ease 9%</a></h4><ul><li>Thinly traded nano cap CareDx (<a href='https://seekingalpha.com/symbol/CDNA' title='CareDx'>CDNA</a> <font color='red'>-8.7%</font>) slumps on average volume (along with most healthcare stocks). In an <a href=\"https://seekingalpha.com/filing/3506678\" target=\"_blank\">8-K filed today</a>, the company reported that it will not meet the SEC's extended deadline for filing its 2016 10-K. It says it will do so \"as promptly as possible\" but cannot provide a specific target date.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257682\" data-linked=\"CareDx still not there with 2016 annual report; shares ease 9%\" data-tweet=\"$CDNA - CareDx still not there with 2016 annual report; shares ease 9% https://seekingalpha.com/news/3257682-caredx-still-not-2016-annual-report-shares-ease-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3257682-caredx-still-not-2016-annual-report-shares-ease-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257680\" data-ts=\"1492542076\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257680-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MVIS' title='Microvision, Inc.'>MVIS</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/NLST' title='Netlist, Inc.'>OTC:NLST</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/SSYS' title='Stratasys, Inc.'>SSYS</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/CSLT' title='Castlight Health, Inc.'>CSLT</a> <font color='green'>+8%</font>. COOL <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CUDA' title='Barracuda Networks, Inc'>CUDA</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SYX' title='Systemax Inc.'>SYX</a> <font color='red'>-8%</font>. MSDI <font color='red'>-7%</font>. WILN <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257680\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$MVIS $NLST $SSYS - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3257680-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3257680-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257673\" data-ts=\"1492538429\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257673-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/LLEX' title='Lilis Energy, Inc.'>LLEX</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ROYT' title='Pacific Coast Oil Trust'>ROYT</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/CCLP' title='CSI Compressco LP'>CCLP</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TGB' title='Taseko Mines Limited'>TGB</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/PLG' title='Platinum Group Metals Ltd'>PLG</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/ARNC' title='Arconic Inc'>ARNC</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/HGT-OLD' title='Hugoton Royalty Trust'>HGT-OLD</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257673\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$LLEX $ROYT $CCLP - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3257673-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3257673-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257669\" data-ts=\"1492537239\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UHS\" target=\"_blank\">UHS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257669-universal-healthminus-2_5-sen-grassley-demands-probe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Universal Health -2.5% as Sen. Grassley demands probe</a></h4><ul><li>It's a day-old story, but apparently only being noticed in the last few minutes.</li><li>Following a news investigation which showed abuses at the Shadow Mountain Behavioral Health facility in Tulsa, Senate Judiciary Chairman Charles Grassley <a href=\"https://www.buzzfeed.com/rosalindadams/sen-grassley-calls-for-federal-probe-into-troubled-youth?utm_term=.pq933dOxW3#.nqe22ODYm2\" target=\"_blank\">has given HHS a deadline</a> to report back to him on what steps it's taking to probe Universal Health (<a href='https://seekingalpha.com/symbol/UHS' title='Universal Health Services Inc.'>UHS</a> <font color='red'>-2.5%</font>) for abuses.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257669\" data-linked=\"Universal Health -2.5% as Sen. Grassley demands probe\" data-tweet=\"$UHS - Universal Health -2.5% as Sen. Grassley demands probe https://seekingalpha.com/news/3257669-universal-healthminus-2_5-sen-grassley-demands-probe?source=tweet\" data-url=\"https://seekingalpha.com/news/3257669-universal-healthminus-2_5-sen-grassley-demands-probe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257661\" data-ts=\"1492535273\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IP\" target=\"_blank\">IP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257661-paper-stocks-active-after-march-data-read\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Paper stocks active after March data read</a></h4><ul><li>Paper stocks are showing some volatility after March industry data indicates a strong level of box shipments and a drop in inventories.</li><li>It's a strong read ahead of an announcement on April 21 by Pulp &amp; Paper Week on prices.</li><li>Source: Bloomberg</li><li>On watch: International Paper (<a href='https://seekingalpha.com/symbol/IP' title='International Paper Co.'>IP</a> <font color='green'>+2%</font>), KapStone Paper and Packaging Corp (<a href='https://seekingalpha.com/symbol/KS' title='KapStone Paper and Packaging Corporation'>KS</a> <font color='green'>+1.9%</font>), Graphic Packaging Holding (<a href='https://seekingalpha.com/symbol/GPK' title='Graphic Packaging Holding Company'>GPK</a> <font color='green'>+0.6%</font>), Packaging Corp of America (<a href='https://seekingalpha.com/symbol/PKG' title='Packaging Corporation Of America'>PKG</a> <font color='green'>+1.3%</font>) and WestRock (<a href='https://seekingalpha.com/symbol/WRK' title='WestRock Company'>WRK</a> <font color='green'>+0.6%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3257661\" data-linked=\"Paper stocks active after March data read\" data-tweet=\"$IP $IP $KS - Paper stocks active after March data read https://seekingalpha.com/news/3257661-paper-stocks-active-after-march-data-read?source=tweet\" data-url=\"https://seekingalpha.com/news/3257661-paper-stocks-active-after-march-data-read\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257659\" data-ts=\"1492534878\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257659-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/BYFC' title='Broadway Financial Corporation'>BYFC</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ATLC' title='Atlanticus Holdings Corp.'>ATLC</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/OPHC' title='OptimumBank Holdings, Inc.'>OPHC</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257659\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$BYFC $ATLC $OPHC - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3257659-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3257659-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257655\" data-ts=\"1492533876\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JNJ\" target=\"_blank\">JNJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257655-j-and-js-3_4-post-earnings-decline-leads-healthcare-lower-unh-rare-gainer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J&amp;J&#39;s 3.4% post-earnings decline leads healthcare lower; UNH a rare gainer</a></h4><ul><li>The company beat on the bottom line, <a href=\"https://seekingalpha.com/news/3257512-j-and-j-q1-top-line-2-percent-earnings-1-percent\" target=\"_blank\">but revenues fell short </a>of estimates thanks a slowdown in pharmaceutical sales.</li><li>Speaking on the earnings call, CFO Dominic Caruso says J&amp;J (<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a> <font color='red'>-3.5%</font>) continues to evaluate options for its diabetes unit. He sees pricing pressure and paying pressure for&nbsp;for Xarelto and Invokana, and is happy to see little impact from&nbsp;biosimilar competition on Remicade.</li><li>Weighing in on results, Cowen bull Joshua Jennings says the growth slowdown makes the Actelion acquisition more timely than previously thought. Source: Bloomberg's Tatiana Darie.</li><li>Other players: Merck (<a href='https://seekingalpha.com/symbol/MCK' title='McKesson Corporation'>MCK</a> <font color='red'>-5.9%</font>), Bristol-Myers (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-0.1%</font>), Gilead (<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color='red'>-1.5%</font>), Eli Lilly (<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color='red'>-1.1%</font>), AbbVie (<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color='red'>-1.7%</font>).</li><li>A rare green name in healthcare is UnitedHealth (<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a> <font color='green'>+1%</font>) after <a href=\"https://seekingalpha.com/news/3257506-unitedhealth-q1-revenues-9-percent-non-gaap-eps-31-percent-updates-2017-guidance-shares-2\" target=\"_blank\">beating on both lines</a>. Speaking on the earnings call, CEO Stephen Hemsley says Q2 results are likely to be inline with that seen in Q1.</li><li>Other insurers: Aetna (<a href='https://seekingalpha.com/symbol/AET' title='Aetna, Inc.'>AET</a> <font color='red'>-0.8%</font>), Humana (<a href='https://seekingalpha.com/symbol/HUM' title='Humana Inc.'>HUM</a> <font color='red'>-0.3%</font>), WellCare (<a href='https://seekingalpha.com/symbol/WCG' title='WellCare Health Plans, Inc.'>WCG</a> <font color='red'>-0.4%</font>)</li><li>Also at work is Cardinal Health's&nbsp;<font color='red'>11.6% plunge</font>&nbsp;after its <a href=\"https://seekingalpha.com/news/3257545-soft-guidance-sinks-cardinal-shares-12-percent-premarket\" target=\"_blank\">weak guidance</a>.</li><li>The Health Care SPDR (<a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a> <font color='red'>-1.4%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a>, <a href='https://seekingalpha.com/symbol/IYH' title='iShares U.S. Healthcare ETF'>IYH</a>, <a href='https://seekingalpha.com/symbol/VHT' title='Vanguard Health Care ETF'>VHT</a>, <a href='https://seekingalpha.com/symbol/HQH' title='Tekla Healthcare Investors'>HQH</a>, <a href='https://seekingalpha.com/symbol/CURE' title='Direxion Daily Healthcare Bull 3x Shares ETF'>CURE</a>, <a href='https://seekingalpha.com/symbol/FXH' title='First Trust Health Care AlphaDEX ETF'>FXH</a>, <a href='https://seekingalpha.com/symbol/FHLC' title='Fidelity MSCI Health Care Index ETF'>FHLC</a>, <a href='https://seekingalpha.com/symbol/RXL' title='ProShares Ultra Health Care ETF'>RXL</a>, <a href='https://seekingalpha.com/symbol/THQ' title='Tekla Healthcare Opportunities Fund'>THQ</a>, <a href='https://seekingalpha.com/symbol/RYH' title='Invesco S&P Equal Weight Health Care ETF'>RYH</a>, <a href='https://seekingalpha.com/symbol/RXD' title='ProShares UltraShort Health Care ETF'>RXD</a>, <a href='https://seekingalpha.com/symbol/SICK' title='Daily Healthcare Bear 3x Shares ETF'>SICK</a>, <a href='https://seekingalpha.com/symbol/BTEC' title='Principal Healthcare Innovators Index ETF'>BTEC</a>, <a href='https://seekingalpha.com/symbol/HCRF' title='iShares Edge MSCI Multifactor Healthcare ETF'>HCRF</a>, <a href='https://seekingalpha.com/symbol/JHMH' title='John Hancock Multifactor Healthcare ETF'>JHMH</a>, <a href='https://seekingalpha.com/symbol/LNGR' title='Global X Longevity Thematic ETF'>LNGR</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3257655\" data-linked=\"J&amp;J&#39;s 3.4% post-earnings decline leads healthcare lower; UNH a rare gainer\" data-tweet=\"$JNJ $JNJ $MCK - J&amp;J&#39;s 3.4% post-earnings decline leads healthcare lower; UNH a rare gainer https://seekingalpha.com/news/3257655-j-and-js-3_4-post-earnings-decline-leads-healthcare-lower-unh-rare-gainer?source=tweet\" data-url=\"https://seekingalpha.com/news/3257655-j-and-js-3_4-post-earnings-decline-leads-healthcare-lower-unh-rare-gainer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>47&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257654\" data-ts=\"1492533641\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISH\" target=\"_blank\">DISH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257654-ncaa-mens-tourney-gives-sling-tv-leg-up-in-programmatic-ads\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NCAA men&#39;s tourney gives Sling TV leg up in programmatic ads</a></h4><ul>   <li>Sling TV (<a href=\"http://seekingalpha.com/symbol/DISH\" target=\"_blank\">DISH</a> <font color='red'>-2%</font>) reports a <a href=\"http://www.multichannel.com/news/advanced-advertising/sling-tv-touts-rise-programmatic-ad-sales/412256\" target=\"_blank\">sharp rise in programmatic ad sales</a> during the NCAA men's basketball tourney, the product of a quiet deal with Tremor Video.</li>    <li>Tremor -- a supply-side platform for the streamer as it transitions toward programmatic sales -- helped boost such sales by 51% for Sling.</li>    <li>&ldquo;Through our partnership with Tremor Video, we&rsquo;ve now worked with thousands of advertisers that are swiftly embracing real-time access to the largest screen in the house,&rdquo; says Dish's Adam Lowy. &ldquo;The momentum started with the NCAA tournament, and now the next TV moment is upon us -&ndash; the NBA Playoffs.&rdquo;</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257654\" data-linked=\"NCAA men&#39;s tourney gives Sling TV leg up in programmatic ads\" data-tweet=\"$DISH - NCAA men&#39;s tourney gives Sling TV leg up in programmatic ads https://seekingalpha.com/news/3257654-ncaa-mens-tourney-gives-sling-tv-leg-up-in-programmatic-ads?source=tweet\" data-url=\"https://seekingalpha.com/news/3257654-ncaa-mens-tourney-gives-sling-tv-leg-up-in-programmatic-ads\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257653\" data-ts=\"1492533601\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257653-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+44%</font>. <a href='https://seekingalpha.com/symbol/GNC' title='GNC Holdings, Inc.'>GNC</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/DXR' title='Daxor Corp'>DXR</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/MVIS' title='Microvision, Inc.'>MVIS</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/CORE' title='Core-Mark Holding Company, Inc.'>CORE</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/NLST' title='Netlist, Inc.'>OTC:NLST</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/CYTK' title='Cytokinetics, Incorporated'>CYTK</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CBLI' title='Cleveland BioLabs, Inc.'>CBLI</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/ADPT' title='Adeptus Health'>ADPT</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/CUDA' title='Barracuda Networks, Inc'>CUDA</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a> <font color='red'>-15%</font>. SPU <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CAH' title='Cardinal Health Inc.'>CAH</a> <font color='red'>-11%</font>. SSH <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/GWW' title='W.W. Grainger, Inc.'>GWW</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/AMCN' title='AirMedia Group Inc'>AMCN</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257653\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$IDXG $GNC $XOMA - Midday Gainers / Losers https://seekingalpha.com/news/3257653-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3257653-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257652\" data-ts=\"1492533505\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TDG\" target=\"_blank\">TDG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257652-transdigmminus-3-on-speculation-of-government-review\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Transdigm -3% on speculation of government review</a></h4><ul>     <li>TransDigm (<a href='https://seekingalpha.com/symbol/TDG' title='TransDigm Group Incorporated'>TDG</a> <font color='red'>-2.9%</font>) sinks after Capitol Forum claims the Department of Defense Inspector General is <a href=\"http://thefly.com/landingPageNews.php?id=2535345&amp;headline=TDG-TransDigm-falls-after-Capitol-Forum-claims-DOD-puts-company-under-review\" target=\"_blank\">investigating the company</a>.</li>     <li>California Rep. Ro Khanna <a href=\"https://seekingalpha.com/news/3252540-transdigm-nearly-another-10-percent-call-government-probe\" target=\"_blank\">last month</a> called for an investigation of TDG for potential waste, fraud and abuse, and according to Capitol Forum, a spokesperson for the Defense Logistics Agency said in an email that the company is \"now under review by the DoD IG.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3257652\" data-linked=\"Transdigm -3% on speculation of government review\" data-tweet=\"$TDG - Transdigm -3% on speculation of government review https://seekingalpha.com/news/3257652-transdigmminus-3-on-speculation-of-government-review?source=tweet\" data-url=\"https://seekingalpha.com/news/3257652-transdigmminus-3-on-speculation-of-government-review\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257650\" data-ts=\"1492532079\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NURO\" target=\"_blank\">NURO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257650-neurometrix-up-12-on-addition-of-bed-bath-beyond-to-quell-distribution-channel\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NeuroMetrix up 12% on addition of Bed, Bath &amp; Beyond to Quell distribution channel</a></h4><ul><li>NeuroMetrix (<a href='https://seekingalpha.com/symbol/NURO' title='NeuroMetrix, Inc.'>NURO</a> <font color='green'>+11.8%</font>) jumps on more than a 5x spike in volume in response to its <a href=\"https://seekingalpha.com/pr/16802141-neurometrix-announces-availability-quell-wearable-pain-relief-technology-bed-bath-and-beyond\" target=\"_blank\">announcement </a>that the Quell device is now available for sale all North American locations of retailer Bed, Bath &amp; Beyond, as well as its e-commerce website.</li><li><a href=\"https://www.quellrelief.com/\" target=\"_blank\">Quell&nbsp;</a>is a neurostimulation device that is worn around the upper calf to provide pain relief due to diabetes, fibromyalgia, arthritis and in the lower back and leg.&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3257650\" data-linked=\"NeuroMetrix up 12% on addition of Bed, Bath &amp; Beyond to Quell distribution channel\" data-tweet=\"$NURO - NeuroMetrix up 12% on addition of Bed, Bath &amp; Beyond to Quell distribution channel https://seekingalpha.com/news/3257650-neurometrix-up-12-on-addition-of-bed-bath-beyond-to-quell-distribution-channel?source=tweet\" data-url=\"https://seekingalpha.com/news/3257650-neurometrix-up-12-on-addition-of-bed-bath-beyond-to-quell-distribution-channel\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257649\" data-ts=\"1492531827\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CUDA\" target=\"_blank\">CUDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257649-barracuda-networks-slides-16-investors-fret-renewal-rate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barracuda Networks slides 16% as investors fret renewal rate</a></h4><ul>   <li>After a brief <a href=\"https://seekingalpha.com/news/3257402-barracuda-networks-q4-beats-top-bottom-lines\" target=\"_blank\">after-hours rise</a> following its earnings beat yesterday, Barracuda Networks (NYSE:<a href='https://seekingalpha.com/symbol/CUDA' title='Barracuda Networks, Inc'>CUDA</a>) indicated lower this morning and has <font color='red'>tumbled 16.4%</font> on more than 10 times average volume, as analysts soak up details on the firm's renewal rate.</li>    <li>On the company's <a href=\"https://seekingalpha.com/article/4062902-barracuda-networks-cuda-ceo-bj-jenkins-q4-2017-results-earnings-call-transcript?part=single\" target=\"_blank\">earnings call</a>, it guided to Q1 revenues of $90M-$92M (vs. consensus for $91.1M) and billings of $103M-$105M, along with non-GAAP EPS of $0.17-$0.19 (vs. consensus for $0.18).</li>    <li>For the full year, it's guided to revenue of $370M-$380M (vs. consensus for $376.3M), and EPS of $0.73-$0.78 (vs. $0.77 expected).</li>    <li>A declining renewal rate concerned analysts. Piper Jaffray noted the quarter was solid overall, but a renewal rate that fell to 89% from 92% (driven by a drop in multi-year appliance contracts as customers migrate to cloud solutions) is clearly concerning investors; it's lowered its price target to $29 from $32 (24% upside from yesterday's close). Morgan Stanley's Melissa Gorham adds U.S. revenue growth underperformed the total, and trims price target to $24 from $25.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257649\" data-linked=\"Barracuda Networks slides 16% as investors fret renewal rate\" data-tweet=\"$CUDA - Barracuda Networks slides 16% as investors fret renewal rate https://seekingalpha.com/news/3257649-barracuda-networks-slides-16-investors-fret-renewal-rate?source=tweet\" data-url=\"https://seekingalpha.com/news/3257649-barracuda-networks-slides-16-investors-fret-renewal-rate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257646\" data-ts=\"1492531236\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257646-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ZX' title='China Zenix Auto International'>ZX</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> SPU <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/NVFY' title='Nova Lifestyle, Inc.'>NVFY</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/KATE' title='Kate Spade & Company'>KATE</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257646\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$ZXAIY $FTFT $NVFY - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3257646-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3257646-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257635\" data-ts=\"1492529816\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDXG\" target=\"_blank\">IDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257635-unitedhealthcare-to-cover-interpaces-thyrmir-test-shares-up-54\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UnitedHealthcare to cover Interpace&#39;s ThyrMIR test; shares up 54%</a></h4><ul><li>Interpace Diagnostics (<a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+53.7%</font>) jumps on a healthy 38x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/16801364-interpace-announces-coverage-thyramir-unitedhealthcare\" target=\"_blank\">announcement </a>that health insurance giant UnitedHealth will cover its ThyraMIR test as an aid in evaluating indeterminate thyroid nodule fine needle aspirate biopsies.</li><li>Interpace is not currently a contracted, in-network lab provider so the decision will expand its coverage universe, now totaling ~250M patients nationwide.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257635\" data-linked=\"UnitedHealthcare to cover Interpace&#39;s ThyrMIR test; shares up 54%\" data-tweet=\"$IDXG - UnitedHealthcare to cover Interpace&#39;s ThyrMIR test; shares up 54% https://seekingalpha.com/news/3257635-unitedhealthcare-to-cover-interpaces-thyrmir-test-shares-up-54?source=tweet\" data-url=\"https://seekingalpha.com/news/3257635-unitedhealthcare-to-cover-interpaces-thyrmir-test-shares-up-54\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257628\" data-ts=\"1492528408\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLG\" target=\"_blank\">PLG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257628-platinum-group-metals-cuts-2017-production-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Platinum Group Metals cuts 2017 production guidance</a></h4><ul><li>Platinum Group Metals (<a href='https://seekingalpha.com/symbol/PLG' title='Platinum Group Metals Ltd'>PLG</a> <font color='red'>-2.6%</font>) is lower after reporting <a href=\"https://seekingalpha.com/news/3257409-platinum-group-metals-reports-fq2-results\" target=\"_blank\">Q2 earnings</a> and <a href=\"http://www.miningweekly.com/article/ptm-reviews-strategic-alternatives-as-maseves-underperformance-leaves-a-hole-in-pocket-2017-04-18\" target=\"_blank\">cutting its 2017 production guidance</a> to 85K oz. of platinum, palladium, rhodium and gold from 100K oz.</li><li>PLG says it held $25M in cash as of Feb. 28, but would need to source $10M-$15M of additional funding through refinancing existing debt, issuing new debt or equity, or selling project or property interests in order  to achieve positive cash flow and to maintain its working capital  covenants in 2017 under existing loan facilities.</li><li>PLG says delays in underground development, stoping rates and planned tonnages would continue to hurt working capital  requirements until sufficient mined stoped material was produced to  allow mine operations to generate positive cash flow.</li><li>PLG's flagship Maseve mine in South Africa reported its best-ever production in March of 2,598 oz., but the result was below target and  did not offset lower January and February results of 1,351 oz. and 1,193 oz., respectively.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257628\" data-linked=\"Platinum Group Metals cuts 2017 production guidance\" data-tweet=\"$PLG - Platinum Group Metals cuts 2017 production guidance https://seekingalpha.com/news/3257628-platinum-group-metals-cuts-2017-production-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3257628-platinum-group-metals-cuts-2017-production-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257627\" data-ts=\"1492528257\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RF\" target=\"_blank\">RF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257627-regions-financialminus-4-after-results-and-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Regions Financial -4% after results and outlook</a></h4><ul><li>Q1 net income of $278M or $0.23 per share vs. $257M and $0.20 one year ago.</li><li>Net interest income of $859M flat Y/Y, with NIM up six basis points to 3.25%. Loans and leases down 2% Y/Y, with consumer lending down 2%, business lending down 4%.</li><li>Noninterest income of $510M about flat on adjusted basis. Mortgage income of $41M up 7.9%; Card &amp; ATM fees of $104M up 9.5%; Service charges of $168M up 5.7%; Capital markets of $32M down 22%.</li><li>Noninterest expenses up 3% Y/Y on adjusted basis.</li><li>Net charge-offs of 0.51% of average loans up 17 basis points Y/Y.</li><li>Full-year outlook: Average loans to be flat-to-down from 2016; deposits stable. Adjusted noninterest income growth of 1-3%; net interest income growth of 3-5%. Net charge-offs of 35-50 basis points.</li><li><a href=\"https://seekingalpha.com/article/4063026-regions-financial-corporation-2017-q1-results-earnings-call-slides\" target=\"_blank\">Conference call slide presentation</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3257474-regions-financial-beats-0_01-revenue-line\" target=\"_blank\">Regions Financial beats by $0.01,  revenue in-line</a> (April 18)</li><li><a href='https://seekingalpha.com/symbol/RF' title='Regions Financial Corporation'>RF</a>&nbsp;<font color='red'>-4.4%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3257627\" data-linked=\"Regions Financial -4% after results and outlook\" data-tweet=\"$RF - Regions Financial -4% after results and outlook https://seekingalpha.com/news/3257627-regions-financialminus-4-after-results-and-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3257627-regions-financialminus-4-after-results-and-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257593\" data-ts=\"1492527654\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257593-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/IMNP' title='Immune Pharmaceuticals Inc.'>OTCQB:IMNP</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/CYTK' title='Cytokinetics, Incorporated'>CYTK</a> <font color='green'>+10%</font>. APRI <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CBLI' title='Cleveland BioLabs, Inc.'>CBLI</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/ADPT' title='Adeptus Health'>ADPT</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/RTTR' title='Ritter Pharmaceuticals'>RTTR</a> <font color='red'>-8%</font>. SSH <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257593\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$XOMA $IMNPQ $AKTX - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3257593-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3257593-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257624\" data-ts=\"1492527538\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GS\" target=\"_blank\">GS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257624-goldmanminus-4-after-disappointing-trading-revenue-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman -4% after disappointing trading revenue results</a></h4><ul><li>\"Ultimately we didn't navigate the market well,\" says new deputy CFO Marty Chavez (he fully takes over from Harvey Schwarz this month), speaking to the bank's flat FICC revenues vs. double-digit gains reported by JPMorgan, Citi, and Bank of America.</li><li>He notes low volatility in the dollar/euro pair and as well as in crude oil - which hits Goldman (<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a> <font color='red'>-4.1%</font>) harder than peers thanks to its relatively large commodity business.</li><li>More from Chavez: \"No quarter defines the franchise ... There&nbsp;are always things we can do better.\"</li><li>The bulls at Credit Suisse aren't fazed, saying it would be foolish to bet against Goldman taking a nice piece of boosted capital markets revenues as economic conditions improve and regulatory burdens ease.</li><li><a href=\"http://www.wsj.com/livecoverage/bofa-goldman-report-earnings\" target=\"_blank\"><em>WSJ</em> blog</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3257527-goldman-sees-trading-revenue-bump-q1-shares-3_65-percent-premarket\" target=\"_blank\">Goldman sees no trading revenue bump in Q1; shares down 3.65% premarket</a> (April 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3257624\" data-linked=\"Goldman -4% after disappointing trading revenue results\" data-tweet=\"$GS - Goldman -4% after disappointing trading revenue results https://seekingalpha.com/news/3257624-goldmanminus-4-after-disappointing-trading-revenue-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3257624-goldmanminus-4-after-disappointing-trading-revenue-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257621\" data-ts=\"1492527286\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SOUHY\" target=\"_blank\">SOUHY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257621-south32-abandons-deal-to-buy-australian-coal-mine-from-peabody\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">South32 abandons deal to buy Australian coal mine from Peabody</a></h4><ul>     <li>South32 (<a href='https://seekingalpha.com/symbol/SOUHY' title='South32 Ltd. ADR'>OTCPK:SOUHY</a> <font color='red'>-1.1%</font>) <a href=\"http://www.marketwatch.com/story/south32-drops-plan-to-buy-peabody-mine-2017-04-18\" target=\"_blank\">scuttles a $200M deal</a> to buy Peabody Energy's (<a href='https://seekingalpha.com/symbol/BTU' title='Peabody Energy Corp.'>BTU</a> <font color='green'>+2.5%</font>) Metropolitan coal mine in Australia amid competition concerns about the supply of coal to local steel makers.</li>     <li>South32, the miner spun out of BHP Billiton in 2015, <a href=\"https://seekingalpha.com/news/3220694-peabody-energy-sell-australian-coal-mine-south32-200m\" target=\"_blank\">agreed in November</a> to buy the mine and an associated 17% stake in the Port Kembla Coal Terminal, located south of Sydney.</li><li>BTU says it is \"surprised that South32 and [Australian regulators] reached an impasse, given both the  physical synergies and the global nature of the metallurgical coal  markets... On  the other hand, we see continuing opportunities given Metropolitan's  quality coking coals and port location.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257621\" data-linked=\"South32 abandons deal to buy Australian coal mine from Peabody\" data-tweet=\"$SOUHY $SOUHY $BTU - South32 abandons deal to buy Australian coal mine from Peabody https://seekingalpha.com/news/3257621-south32-abandons-deal-to-buy-australian-coal-mine-from-peabody?source=tweet\" data-url=\"https://seekingalpha.com/news/3257621-south32-abandons-deal-to-buy-australian-coal-mine-from-peabody\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257619\" data-ts=\"1492526970\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VZ\" target=\"_blank\">VZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257619-corning-jumps-verizon-agrees-to-fiber-deal-of-least-1_05b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Corning jumps as Verizon agrees to fiber deal of at least $1.05B</a></h4><ul>     <li>Verizon (NYSE:<a href='https://seekingalpha.com/symbol/VZ' title='Verizon Communications'>VZ</a>) has agreed to a $1.05B deal with Corning (NYSE:<a href='https://seekingalpha.com/symbol/GLW' title='Corning Inc.'>GLW</a>) to <a href=\"http://www.cnbc.com/2017/04/18/verizon-agrees-to-1-05-billion-fiber-optic-cable-deal-to-grow-its-fios-platform.html\" target=\"_blank\">buy millions of miles of fiber</a> to grow its FiOS platform.</li>     <li><a href='https://seekingalpha.com/symbol/GLW' title='Corning Inc.'>GLW</a> is spiking on the news, <font color='green'>up 0.8%</font>.</li>     <li>Corning will provide, and Verizon will buy, up to 12.4M miles of optical fiber per year in 2018 through 2020. The $1.05B is a minimum commitment.</li>     <li>The goal is to \"improve Verizon's 4G LTE coverage, speed the deployment of 5G, and deliver high-speed broadband to homes and businesses of all sizes,\" Verizon says.</li><li><strong>Updated 11:01 a.m.:</strong>&nbsp;<a href=\"https://seekingalpha.com/pr/16802094-verizon-agrees-1_05-billion-three-year-minimum-purchase-agreement-corning-next-generation\" target=\"_blank\">Verizon's press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3257619\" data-linked=\"Corning jumps as Verizon agrees to fiber deal of at least $1.05B\" data-tweet=\"$VZ $VZ $GLW - Corning jumps as Verizon agrees to fiber deal of at least $1.05B https://seekingalpha.com/news/3257619-corning-jumps-verizon-agrees-to-fiber-deal-of-least-1_05b?source=tweet\" data-url=\"https://seekingalpha.com/news/3257619-corning-jumps-verizon-agrees-to-fiber-deal-of-least-1_05b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257618\" data-ts=\"1492526754\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMC\" target=\"_blank\">OMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257618-omnicomminus-2_8-after-q1-beats-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Omnicom -2.8% after Q1 beats expectations</a></h4><ul>   <li>Omnicom (NYSE:<a href='https://seekingalpha.com/symbol/OMC' title='Omnicom Group Inc.'>OMC</a>) is <font color='red'>2.8% lower</font> despite a <a href=\"https://seekingalpha.com/news/3257488-omnicom-beats-0_01-beats-revenue\" target=\"_blank\">Q1 earnings report</a> where growth in the UK and Europe (seemingly unaffected by Brexit) led to a beat on revenue and the bottom line.</li>    <li>EPS rose 13.3% on a headline basis, and revenues rose 2.6%, weighed down by a negative foreign exchange impact of 1.2%.</li>    <li>Organic revenue growth was up 4.4%. Organic growth by region: North America, 1.1%; UK, 8.1%; Euro Markets and other Europe, 8.2%; Asia Pacific, 9.1%; Latin America, 5.4%; Middle East and Africa, 37.9%.</li>    <li>Organic growth by discipline: Advertising, 6.4%; CRM, 2.1%; Public Relations, 1.8%; Specialty Communications, 3.3%.</li>    <li><a href=\"http://event.on24.com/wcc/r/1325373/FDBCDD78A9E40CEC52DEAE81316819C6\" target=\"_blank\">Earnings call</a></li>    <li><a href=\"https://seekingalpha.com/pr/16801165-omnicom-group-reports-first-quarter-2017-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3257618\" data-linked=\"Omnicom -2.8% after Q1 beats expectations\" data-tweet=\"$OMC - Omnicom -2.8% after Q1 beats expectations https://seekingalpha.com/news/3257618-omnicomminus-2_8-after-q1-beats-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3257618-omnicomminus-2_8-after-q1-beats-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257610\" data-ts=\"1492525796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257610-bond-bulls-in-charge-10-year-hits-new-2017-low\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bond bulls in charge as 10-year hits new 2017 low</a></h4><ul><li>The 10-year Treasury yield is down another five basis points to 2.20% this morning, matching yesterday's intraday low, and now at a level not seen since just a few days after November's election (it stood at about 1.9% prior to the Trump victory).</li><li>In economic news today, <a href=\"https://seekingalpha.com/news/3257549-march-housing-starts-shy-estimates\" target=\"_blank\">housing starts for March</a> missed estimates, but the trend remains strong. In equity markets, stocks here are&nbsp;<font color='red'>down only modestly</font>, but&nbsp;<font color='red'>lower by nearly 1%</font>&nbsp;in Europe.</li><li>Looking <a href=\"http://www.cmegroup.com/trading/interest-rates/stir/30-day-federal-fund.html\" target=\"_blank\">at short-term rate markets</a>, they're pricing in only a little more than one rate hike for the rest of the year, even as most Fed speakers are promising two-three more moves.</li><li><a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='green'>+0.8%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='red'>-1.6%</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>, <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>, <a href='https://seekingalpha.com/symbol/TMV' title='Direxion Daily 20+ Year Treasury Bear 3x Shares ETF'>TMV</a>, <a href='https://seekingalpha.com/symbol/TBF' title='ProShares Short 20+ Year Treasury ETF'>TBF</a>, <a href='https://seekingalpha.com/symbol/EDV' title='Vanguard Extended Duration Treasury ETF'>EDV</a>, <a href='https://seekingalpha.com/symbol/TMF' title='Direxion Daily 30-Year Treasury Bull 3x Shares ETF'>TMF</a>, <a href='https://seekingalpha.com/symbol/TTT' title='ProShares UltraPro Short 20+ Year Treasury ETF'>TTT</a>, <a href='https://seekingalpha.com/symbol/ZROZ' title='PIMCO 25+ Year Zero Coupon U.S. Treasury Index ETF'>ZROZ</a>, <a href='https://seekingalpha.com/symbol/VGLT' title='Vanguard Long-Term Government Bond Index ETF'>VGLT</a>, <a href='https://seekingalpha.com/symbol/TLH' title='iShares 10-20 Year Treasury Bond ETF'>TLH</a>, <a href='https://seekingalpha.com/symbol/UBT' title='ProShares Ultra 20+ Year Treasury ETF'>UBT</a>, <a href='https://seekingalpha.com/symbol/DLBS' title='iPath U.S. Treasury Long Bond Bear ETN'>DLBS</a>, <a href='https://seekingalpha.com/symbol/TLO' title='SPDR Barclays Long Term Treasury ETF'>TLO</a>, <a href='https://seekingalpha.com/symbol/VUSTX' title='Vanguard Long Term Treasury Fund Inv'>VUSTX</a>, <a href='https://seekingalpha.com/symbol/DLBL' title='iPath U.S. Treasury Long Bond Bull ETN'>DLBL</a>, <a href='https://seekingalpha.com/symbol/TYBS' title='Direxion Daily 20+ Year Treasury Bear 1x Shares ETF'>TYBS</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3257610\" data-linked=\"Bond bulls in charge as 10-year hits new 2017 low\" data-tweet=\"$TLT $TBT $TMV - Bond bulls in charge as 10-year hits new 2017 low https://seekingalpha.com/news/3257610-bond-bulls-in-charge-10-year-hits-new-2017-low?source=tweet\" data-url=\"https://seekingalpha.com/news/3257610-bond-bulls-in-charge-10-year-hits-new-2017-low\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257608\" data-ts=\"1492525344\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARNC\" target=\"_blank\">ARNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257608-arconic-reverses-mondays-advance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arconic reverses Monday&#39;s advance</a></h4><ul><li>Arconic (<a href='https://seekingalpha.com/symbol/ARNC' title='Arconic Inc'>ARNC</a> <font color='red'>-5%</font>) shares are giving back yesterday's gains following news that Klaus Kleinfeld <a href=\"https://seekingalpha.com/news/3257288-arconics-kleinfeld-chairman-ceo-shares-plus-5-percent-premarket\" target=\"_blank\">resigned</a> after he sent a letter in \"poor judgment\" to Elliott Management.</li><li>\"We've never seen anything like this before,\" <a href=\"https://www.bloomberg.com/news/articles/2017-04-18/kleinfeld-s-rogue-response-seals-fate-as-elliott-prods-arconic\" target=\"_blank\">said</a> Carol Levenson, research director at Gimme Credit. \"Arconic looked as though it was determined to fight Elliott to the finish and as recently as last week was in full support (along with some of its major customers) of its current CEO.\"</li><li><strong>Update: </strong>JPMorgan has <a href=\"http://blogs.barrons.com/stockstowatchtoday/2017/04/18/arconic-ceos-exit-is-good-news-but/?mod=yahoobarrons&amp;ru=yahoo\" target=\"_blank\">initiated</a> the stock with with a Neutral rating and Dec 2017 price target of $29. \"We view Klaus Kleinfeld&rsquo;s resignation yesterday as a plus and see significant EPS growth ahead but after ARNC&rsquo;s 44% run YTD vs 5% for the S&amp;P 500 we believe the market already expects results well ahead of consensus.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3257608\" data-linked=\"Arconic reverses Monday&#39;s advance\" data-tweet=\"$ARNC - Arconic reverses Monday&#39;s advance https://seekingalpha.com/news/3257608-arconic-reverses-mondays-advance?source=tweet\" data-url=\"https://seekingalpha.com/news/3257608-arconic-reverses-mondays-advance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257603\" data-ts=\"1492524564\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAC\" target=\"_blank\">BAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257603-moynihan-not-just-rates-play\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moynihan: We&#39;re not just a rates play</a></h4><ul><li>A $700M increase in net interest income certainly helped Bank of America's (NYSE:<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a>) Q1, but CEO Brian Moynihan reminds that 60% of the bank's revenue growth last quarter was from non-interest sources (like trading).</li><li>Investors, however, tend to pay less for trading revenues which can be rather lumpy.</li><li>Turning to expenses, the bank - for now - is sticking with its promise to cut another $5B in annual expenses by 2018. Trouble is, with business growing, one would expect expenses to have to go up at least somewhat. Sure enough, noninterest expenses in Q1 of $14.848B were up a hair from a year earlier.</li><li>CFO Paul Donofrio reminds that the expense promise was based on the economic environment at that time. \"If things get better, we'd have to adjust.\"</li><li>The good news on earnings overall and trading in particular has seemingly been priced in thanks to the results from JPMorgan and Citigroup last week, not to mention a 40% advance in BofA over the last six months. After an early pop, shares are&nbsp;<font color='red'>lower by 0.5%</font>&nbsp;at current writing.</li><li><a href=\"http://www.wsj.com/livecoverage/bofa-goldman-report-earnings\" target=\"_blank\"><em>WSJ</em> blog</a></li><li><a href=\"https://seekingalpha.com/article/4062987-bank-america-corporation-2017-q1-results-earnings-call-slides\" target=\"_blank\">Earnings call slides</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3257505-surge-trading-revenue-boosts-bofas-quarter\" target=\"_blank\">Surge in trading revenue boosts BofA's quarter</a> (April 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3257603\" data-linked=\"Moynihan: We&#39;re not just a rates play\" data-tweet=\"$BAC - Moynihan: We&#39;re not just a rates play https://seekingalpha.com/news/3257603-moynihan-not-just-rates-play?source=tweet\" data-url=\"https://seekingalpha.com/news/3257603-moynihan-not-just-rates-play\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257601\" data-ts=\"1492524338\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLCE\" target=\"_blank\">PLCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257601-childrens-place-swings-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Children&#39;s Place swings lower</a></h4><ul> <li>Shares of Children's Place (NASDAQ:<a href='https://seekingalpha.com/symbol/PLCE' title='The Children&#39;s Place Retail Stores, Inc.'>PLCE</a>) are <font color='red'>down 3.02%</font> in a move that is being attributed to a negative mention by data tracking firm M Science.</li> <li>M Science warns that soft transaction trends could tip an earnings miss for the retailer (<a href=\"https://twitter.com/thenotablecalls/status/854328180227940354\" target=\"_blank\">via NotableCalls</a>).</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3257601\" data-linked=\"Children&#39;s Place swings lower\" data-tweet=\"$PLCE - Children&#39;s Place swings lower https://seekingalpha.com/news/3257601-childrens-place-swings-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3257601-childrens-place-swings-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257587\" data-ts=\"1492524037\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRS\" target=\"_blank\">AMRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257587-amyris-deepens-relationship-contract-manufacturer-blue-california-china-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amyris deepens relationship with contract manufacturer Blue California with China deal</a></h4><ul><li>Amyris (<a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a> <font color='red'>-13.1%</font>) <a href=\"https://seekingalpha.com/pr/16801292-amyris-agrees-exclusive-china-manufacturing-blue-california-enabling-continued-record-product\" target=\"_blank\">expands its relationship</a> with preferred contract manufacturer Phyto Tech Corp (Blue California) with a new agreement under which it will have access to Blue's fermentation manufacturing in China and Blue's affiliates will provide the capital to produce No Compromise ingredients there.</li><li>Amyris says it expects to generate at least $50M in revenue over the next 12-18 months in China.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3257573-amyris-cuts-10m-previously-announced-q4-full-year-revenue-due-deal-blue-california-shares\" target=\"_blank\">Amyris cuts $10M off previously announced Q4 and full-year revenue due in deal with Blue California; shares slip 12% premarket</a> (April 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3257587\" data-linked=\"Amyris deepens relationship with contract manufacturer Blue California with China deal\" data-tweet=\"$AMRS - Amyris deepens relationship with contract manufacturer Blue California with China deal https://seekingalpha.com/news/3257587-amyris-deepens-relationship-contract-manufacturer-blue-california-china-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3257587-amyris-deepens-relationship-contract-manufacturer-blue-california-china-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257594\" data-ts=\"1492523771\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTS\" target=\"_blank\">TTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257594-post-earnings-rip-for-tile-shop\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Post-earnings rip for Tile Shop</a></h4><ul> <li>Shares of Tile Shop (<a href='https://seekingalpha.com/symbol/TTS' title='Tile Shop Holdings, Inc.'>TTS</a> <font color='green'>+13.1%</font>) move higher after <a href=\"https://seekingalpha.com/pr/16801438-tile-shop-reports-first-quarter-2017-results\" target=\"_blank\">Q1</a> results arrive ahead of the consensus estimate of analysts.</li> <li>Comparable sales were up 4.9% during the quarter.</li> <li>The company's gross margin rate of 70.3% was down 20 bps from last year's level.</li> <li>Looking ahead, Tile Shop expects sales of $350M to $370M and EPS of $0.50 to $0.57. Comparable store sales are expected to increase at a low to mid single digit clip.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3257528-tile-shop-holdings-beats-0_02-beats-revenue\" target=\"_blank\">Tile Shop Holdings beats by $0.02, beats on revenue</a> (April 18)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257594\" data-linked=\"Post-earnings rip for Tile Shop\" data-tweet=\"$TTS $TTSH - Post-earnings rip for Tile Shop https://seekingalpha.com/news/3257594-post-earnings-rip-for-tile-shop?source=tweet\" data-url=\"https://seekingalpha.com/news/3257594-post-earnings-rip-for-tile-shop\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257592\" data-ts=\"1492523553\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCX\" target=\"_blank\">FCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257592-freeport-gets-initial-approval-to-resume-indonesia-copper-exports\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Freeport gets initial approval to resume Indonesia copper exports</a></h4><ul>     <li>Freeport McMoRan (<a href='https://seekingalpha.com/symbol/FCX' title='Freeport-McMoRan Inc.'>FCX</a> <font color='red'>-1.9%</font>) has <a href=\"http://www.reuters.com/article/indonesia-freeport-idUSJ9N19L008\" target=\"_blank\">received preliminary approval</a> to resume copper concentrate exports from its Indonesian unit and is now in the process of obtaining an export permit, a company spokesman says.</li>     <li>The government halted FCX's copper concentrate exports in January under new rules that require the company to adopt a special license, pay new taxes and royalties, divest a 51% stake in its operations and relinquish arbitration rights.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257592\" data-linked=\"Freeport gets initial approval to resume Indonesia copper exports\" data-tweet=\"$FCX - Freeport gets initial approval to resume Indonesia copper exports https://seekingalpha.com/news/3257592-freeport-gets-initial-approval-to-resume-indonesia-copper-exports?source=tweet\" data-url=\"https://seekingalpha.com/news/3257592-freeport-gets-initial-approval-to-resume-indonesia-copper-exports\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257589\" data-ts=\"1492523328\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257589-wall-street-stream-of-consciousness-on-netflix\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wall Street stream of consciousness on Netflix</a></h4><ul> <li>Bank of America Merrill Lynch turns its focus on Netflix (<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a> <font color='red'>-2%</font>) to Q2, with new and original content expected to drive subscriber growth. The firm notes that the quarter-to-date net subscriber growth already looks strong. BAML moves its price target on NFLX to $184 (Street high).</li> <li>Raymond James and Nomura Instinet both think that Netflix's international growth will continue to drive improved profitability. Both firms have a PT of $165 on the streamer.</li> <li>Wedbush analyst Michael Pachter warns on the \"greater fool\" theory on Netflix that it can grow into its valuation through prices hikes. \"The truth is their content costs will rise as they choose to raise prices,\" he says.</li> <li>Meanwhile, Credit Suisse isn't looking at Netflix earnings, but is dishing out thoughts on a potential takeover of the company by Apple. A $60B valuation is called \"ambitious\" by the firm. \"However, given the desirability of providing video streaming content to Apple users and devices, it is a possibility with improved terms with content owners and potentially bundling with other Apple services,\" reads the CS note.</li> <li>Sources: Bloomberg and <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/04/9310728/credit-suisses-take-on-apple-services-business-potential\" target=\"_blank\">Benzinga</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3257379-netflix-beats-0_03-revenue-line\" target=\"_blank\">Netflix beats by $0.03,  revenue in-line</a> (April 17)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3257384-netflix-subscriber-growth-falls-short-estimates\" target=\"_blank\">Netflix subscriber growth falls short of estimates</a> (April 17)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257589\" data-linked=\"Wall Street stream of consciousness on Netflix\" data-tweet=\"$NFLX - Wall Street stream of consciousness on Netflix https://seekingalpha.com/news/3257589-wall-street-stream-of-consciousness-on-netflix?source=tweet\" data-url=\"https://seekingalpha.com/news/3257589-wall-street-stream-of-consciousness-on-netflix\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257581\" data-ts=\"1492522151\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSYS\" target=\"_blank\">SSYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257581-stratasysplus-4_5-piper-upgrades-on-demand-trends\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stratasys +4.5% as Piper upgrades on demand trends</a></h4><ul>   <li>Stratasys (NASDAQ:<a href='https://seekingalpha.com/symbol/SSYS' title='Stratasys, Inc.'>SSYS</a>) is <font color='green'>up 4.5%</font> premarket after Piper Jaffray raised its rating on the stock to Overweight.</li>    <li>Reseller channel checks show demand is improving, says analyst Troy Jensen, with a \"meaningful uptick\" for the second straight quarter.</li>    <li>Meanwhile, rival 3D Systems (<a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corp.'>DDD</a>, which Jensen rates at Underweight) still has a problem with systems demand, he notes.</li>    <li>The firm raised its price target to $28 from $21, implying 31% upside.</li>    <li>Premarket: <a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corp.'>DDD</a> <font color='green'>+1.1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257581\" data-linked=\"Stratasys +4.5% as Piper upgrades on demand trends\" data-tweet=\"$SSYS $SSYS $DDD - Stratasys +4.5% as Piper upgrades on demand trends https://seekingalpha.com/news/3257581-stratasysplus-4_5-piper-upgrades-on-demand-trends?source=tweet\" data-url=\"https://seekingalpha.com/news/3257581-stratasysplus-4_5-piper-upgrades-on-demand-trends\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257579\" data-ts=\"1492521964\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTHT\" target=\"_blank\">HTHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257579-benchmark-sees-upside-for-china-lodging\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Benchmark sees upside for China Lodging</a></h4><ul> <li>Benchmark initiates coverage on China Lodging Group (NASDAQ:<a href='https://seekingalpha.com/symbol/HTHT' title='Huazhu Group Limited ADR'>HTHT</a>) with a Buy rating.</li> <li>The investment firm sets a price target of $68 on the hotel stock. The 52-week high on HTHT is $64.32.</li> <li>China Lodging reported an improved Q1 RevPAR mark yesterday in a <a href=\"https://seekingalpha.com/pr/16800095-china-lodging-group-limited-announces-preliminary-results-hotel-operation-first-quarter-2017\" target=\"_blank\">preliminary report</a> on Q1 earnings.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3257579\" data-linked=\"Benchmark sees upside for China Lodging\" data-tweet=\"$HTHT - Benchmark sees upside for China Lodging https://seekingalpha.com/news/3257579-benchmark-sees-upside-for-china-lodging?source=tweet\" data-url=\"https://seekingalpha.com/news/3257579-benchmark-sees-upside-for-china-lodging\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257575\" data-ts=\"1492521574\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257575-disruption-starts-to-play-trucking-sector\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Disruption starts to play into the trucking sector</a></h4><ul> <li>Piper Jaffray warns that electric trucks from Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) pose a long-term threat to some trucking names.</li> <li>Cummins (NYSE:<a href='https://seekingalpha.com/symbol/CMI' title='Cummins Inc.'>CMI</a>) and PACCAR (NASDAQ:<a href='https://seekingalpha.com/symbol/PCAR' title='PACCAR Inc.'>PCAR</a>) are downgraded by the firm to Neutral from Overweight due to valuation and the threat of EV disruption.</li> <li>Allison Transmission (NYSE:<a href='https://seekingalpha.com/symbol/ALSN' title='Allison Transmission'>ALSN</a>) is also identified as a supplier with EV risk. Piper notes that WABCO Holdings (NYSE:<a href='https://seekingalpha.com/symbol/WBC' title='WABCO Holdings Inc.'>WBC</a>) is insulated for the most part from the EV threat in trucking.</li> <li>The long-term horizon for trucking could also be influenced by self-driving startups like <a href=\"https://www.recode.net/2017/2/25/14737842/embark-self-driving-trucks-automation\" target=\"_blank\">Embark</a> and Uber (<a href='https://seekingalpha.com/symbol/UBER' title='Uber'>UBER</a>)-owned Otto, which although they aren't expected to be volume players, could lead to some changes within trucking.</li><li>Related trucking industry stocks: <a href='https://seekingalpha.com/symbol/MTOR' title='Meritor, Inc.'>MTOR</a>, <a href='https://seekingalpha.com/symbol/RUSHA' title='Rush Enterprises, Inc.'>RUSHA</a>, <a href='https://seekingalpha.com/symbol/NAV' title='Navistar International Corporation'>NAV</a>, <a href='https://seekingalpha.com/symbol/DDAIF' title='Daimler AG'>OTCPK:DDAIF</a>, <a href='https://seekingalpha.com/symbol/OSK' title='Oshkosh Corporation'>OSK</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257575\" data-linked=\"Disruption starts to play into the trucking sector\" data-tweet=\"$TSLA $TSLA $CMI - Disruption starts to play into the trucking sector https://seekingalpha.com/news/3257575-disruption-starts-to-play-trucking-sector?source=tweet\" data-url=\"https://seekingalpha.com/news/3257575-disruption-starts-to-play-trucking-sector\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>104&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257574\" data-ts=\"1492521526\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257574-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+44%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16801364-interpace-announces-coverage-thyramir-unitedhealthcare\" target=\"_blank\">announcing</a> to cover Interpace's ThyraMIR with UnitedHealthcare.</li><li><a href='https://seekingalpha.com/symbol/GNC' title='GNC Holdings, Inc.'>GNC</a> <font color='green'>+19%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3257494-gnc-holdings-beats-0_03-beats-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/FNJN' title='Finjan Holdings, Inc.'>FNJN</a> <font color='green'>+12%</font>&nbsp;on announcing <a href=\"https://seekingalpha.com/pr/16801520-finjan-generated-25-million-revenues-achieved-profitability-first-quarter-2017\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a> <font color='green'>+9%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16801472-biocept-awarded-additional-patent-japan-expanding-intellectual-property-estate-19-issued\" target=\"_blank\">awarding</a> Japanese Patent No. 6081434 entitled devices and methods of cell capture and analysis.</li><li><a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16801554-cellectar-biosciences-receives-japanese-patent-clr-131-clr-125-treatment-cancer-stem-cells\" target=\"_blank\">receiving</a> the Japanese Patent Office has granted a method of use patent for two of the company&rsquo;s phospholipid drug conjugates (PDCs), CLR 131, the company&rsquo;s lead compound, and CLR 125.</li><li><a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a> <font color='green'>+9%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16801218-xoma-presents-positive-data-pth1r-monoclonal-antibody-program\" target=\"_blank\">announcing</a> positive data from pre-clinical studies investigating the activity of its anti-PTH1R antagonist monoclonal antibody.</li><li><a href='https://seekingalpha.com/symbol/CAB' title='Cabela&#39;s Incorporated'>CAB</a> <font color='green'>+8%</font>.</li><li><a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a> <font color='green'>+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257574\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$IDXG $GNC $FNJN - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3257574-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3257574-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257569\" data-ts=\"1492521168\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257569-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a> <font color='red'>-18%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16801027-arena-pharmaceuticals-announces-pricing-public-offering-common-stock\" target=\"_blank\">pricing</a> equity offering.</li><li><a href='https://seekingalpha.com/symbol/CBLI' title='Cleveland BioLabs, Inc.'>CBLI</a> <font color='red'>-12%</font>.</li><li><a href='https://seekingalpha.com/symbol/CAH' title='Cardinal Health Inc.'>CAH</a> <font color='red'>-12%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16801178-cardinal-health-updates-fiscal-2017-guidance-provides-early-outlook-future-fiscal-years\" target=\"_blank\">announcing</a> 2017 guidance.</li><li><a href='https://seekingalpha.com/symbol/AMCN' title='AirMedia Group Inc'>AMCN</a> <font color='red'>-10%</font>.</li><li><a href='https://seekingalpha.com/symbol/ADPT' title='Adeptus Health'>ADPT</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3257569\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$ARNA $CBLI $CAH - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3257569-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3257569-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257555\" data-ts=\"1492520875\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XOMA\" target=\"_blank\">XOMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257555-xomas-pth1r-antibody-shows-encouraging-action-in-preclinical-testing-shares-ahead-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XOMA&#39;s PTH1R antibody shows encouraging action in preclinical testing; shares ahead 8% premarket</a></h4><ul><li>(NASDAQ:<a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a>) perks up&nbsp;<font color='green'>8%</font>&nbsp;premarket on modestly higher volume in response to its <a href=\"https://seekingalpha.com/pr/16801218-xoma-presents-positive-data-pth1r-monoclonal-antibody-program\" target=\"_blank\">announcement </a>of positive preclinical data related to its anti-PTH1R antagonist monoclonal antibody, a potential first-in-class therapeutic agent to treat hyperparathyroidism and humoral hypercalcemia of malignancy. The results were presented at the American Association for Cancer Research and the Endocrine Society annual meetings several weeks ago.</li><li><em>In vitro</em> PTH1R antagonism produced by the antibody translated to potent <em>in vivo</em> activity. The results showed the anti-PTH1R mAb improved hypercalcemia (excess calcium in the blood) and associated morbidities.</li><li>The company says it aims to out-license the product candidate to an established leader in drug development.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257555\" data-linked=\"XOMA&#39;s PTH1R antibody shows encouraging action in preclinical testing; shares ahead 8% premarket\" data-tweet=\"$XOMA - XOMA&#39;s PTH1R antibody shows encouraging action in preclinical testing; shares ahead 8% premarket https://seekingalpha.com/news/3257555-xomas-pth1r-antibody-shows-encouraging-action-in-preclinical-testing-shares-ahead-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3257555-xomas-pth1r-antibody-shows-encouraging-action-in-preclinical-testing-shares-ahead-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257559\" data-ts=\"1492520387\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCHW\" target=\"_blank\">SCHW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257559-schwabplus-1_7-higher-interest-rates-offset-lower-prices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Schwab +1.7% as higher interest rates more than offset lower prices</a></h4><ul><li>Q1 net income of $564M or $0.39 per share vs. $412M and $0.29 one year ago.</li><li>Pretax profit margin of 40.5% up from 37.1% a year ago. ROE of 15% up 200 basis points Y/Y.</li><li>Higher rates are helping, with net interest revenue of $1B up 29.5% Y/Y.</li><li>Asset management and administration fees of $823M up 17.7% Y/Y.</li><li>Trading revenue of $192M fell 17% Y/Y thanks to commission price cuts.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3257552-charles-schwab-beats-0_02-beats-revenue\" target=\"_blank\">Charles Schwab beats by $0.02, beats on revenue</a> (April 18)</li><li><a href='https://seekingalpha.com/symbol/SCHW' title='The Charles Schwab Corporation'>SCHW</a>&nbsp;<font color='green'>+1.7%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3257559\" data-linked=\"Schwab +1.7% as higher interest rates more than offset lower prices\" data-tweet=\"$SCHW - Schwab +1.7% as higher interest rates more than offset lower prices https://seekingalpha.com/news/3257559-schwabplus-1_7-higher-interest-rates-offset-lower-prices?source=tweet\" data-url=\"https://seekingalpha.com/news/3257559-schwabplus-1_7-higher-interest-rates-offset-lower-prices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257554\" data-ts=\"1492520216\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGLT\" target=\"_blank\">EGLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257554-fda-accepts-egalets-pas-for-oxaydo-10-15-mg-shares-ahead-9-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Egalet&#39;s PAS for OXAYDO 10/15 mg; shares ahead 9% premarket</a></h4><ul><li>Egalet Corporation (<a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a>)&nbsp;<a href=\"https://seekingalpha.com/pr/16801152-egalet-announces-u-s-food-drug-administration-acceptance-file-prior-approval-supplement\" target=\"_blank\">announces</a> that the submission of a prior approval supplement &#40;PAS&#41; for <a href=\"http://www.oxaydo.com/\" target=\"_blank\">OXAYDO</a>&nbsp;(oxycodone HCl, USP) tablets C-II, seeking approval of 10 mg and 15 mg dosage strengths, has been accepted by the FDA.</li><li>The submission is based on a pharmacokinetic study demonstrating bioequivalence of OXAYDO&nbsp; to its reference drug, Roxicodone at the 15 mg dosage strength.</li><li>The FDA will review the OXAYDO 10/15 mg PAS by June 17.</li>                   <li>OXAYDO is an immediate-release oral formulation of oxycodone HCl indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.</li><li>Shares are up&nbsp;<font color='green'>9%</font>&nbsp;premarket but only on 10 shares.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3257554\" data-linked=\"FDA accepts Egalet&#39;s PAS for OXAYDO 10/15 mg; shares ahead 9% premarket\" data-tweet=\"$EGLT $ZCOR - FDA accepts Egalet&#39;s PAS for OXAYDO 10/15 mg; shares ahead 9% premarket https://seekingalpha.com/news/3257554-fda-accepts-egalets-pas-for-oxaydo-10-15-mg-shares-ahead-9-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3257554-fda-accepts-egalets-pas-for-oxaydo-10-15-mg-shares-ahead-9-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257553\" data-ts=\"1492519631\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSI\" target=\"_blank\">VSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257553-vitamin-shoppe-rallies-after-gnc-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vitamin Shoppe rallies after GNC earnings beat</a></h4><ul> <li>Shares of Vitamin Shoppe (NYSE:<a href='https://seekingalpha.com/symbol/VSI' title='Vitamin Shoppe, Inc.'>VSI</a>) shoot higher in premarket action after peer GNC Holdings tops estimates.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3257494-gnc-holdings-beats-0_03-beats-revenue\" target=\"_blank\">GNC Holdings beats by $0.03, beats on revenue</a> (April 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3257502-gnc-holdings-spikes-earnings-beat\" target=\"_blank\">GNC Holdings spikes after earnings beat</a> (April 18)</li> <li>VSI <font color='green'>+4.65%</font> premarket to $20.25.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3257553\" data-linked=\"Vitamin Shoppe rallies after GNC earnings beat\" data-tweet=\"$VSI - Vitamin Shoppe rallies after GNC earnings beat https://seekingalpha.com/news/3257553-vitamin-shoppe-rallies-after-gnc-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3257553-vitamin-shoppe-rallies-after-gnc-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257552\" data-ts=\"1492519568\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCHW\" target=\"_blank\">SCHW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257552-charles-schwab-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Charles Schwab beats by $0.02, beats on revenue</a></h4><ul><li>Charles Schwab (NYSE:<a href='https://seekingalpha.com/symbol/SCHW' title='The Charles Schwab Corporation'>SCHW</a>): Q1 EPS of $0.39 <font color='green'>beats by $0.02</font>.</li><li>Revenue of $2.08B (+18.2% Y/Y) <font color='green'>beats by $20M</font>.</li><li>Shares <font color='green'>+2.31%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16801623-schwab-reports-record-quarterly-net-income-564-million-37-percent'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3257552\" data-linked=\"Charles Schwab beats by $0.02, beats on revenue\" data-tweet=\"$SCHW - Charles Schwab beats by $0.02, beats on revenue https://seekingalpha.com/news/3257552-charles-schwab-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3257552-charles-schwab-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257545\" data-ts=\"1492519437\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAH\" target=\"_blank\">CAH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257545-soft-guidance-sinks-cardinal-shares-down-12-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Soft guidance sinks Cardinal; shares down 12% premarket</a></h4><ul><li>On the heels of the announcement of its $6.1B acquisition of three Medtronic businesses for $6.1B, Cardinal Health (NYSE:<a href='https://seekingalpha.com/symbol/CAH' title='Cardinal Health Inc.'>CAH</a>) releases updated fiscal 2017 guidance that includes a <a href=\"https://seekingalpha.com/pr/16801178-cardinal-health-updates-fiscal-2017-guidance-provides-early-outlook-future-fiscal-years\" target=\"_blank\">softer outlook</a> for non-GAAP EPS, now expected to be at the bottom of the previously announced range of $5.35 - 5.50. The company says generic price deflation, expected to be in the low-double digits, represents a significant headwind in the Pharmaceutical segment.</li><li>Preliminary fiscal 2018 view for non-GAAP EPS is flat to down mid-single digits. Profits in the Medical segment should rise significantly, buoyed by the Medtronic transaction, but several \"company-specific discrete items\" will trim EPS at least $0.50 (about half from generic deflation).</li><li>Fiscal 2019 non-GAAP EPS should grow at least high-single digits versus fiscal 2018.</li><li>Shares are down&nbsp;<font color='red'>12%</font>&nbsp;premarket on robust volume. Fellow drug distributors McKesson (NYSE:<a href='https://seekingalpha.com/symbol/MCK' title='McKesson Corporation'>MCK</a>) (<font color='red'>-4%</font>) and AmerisourceBergen (NYSE:<a href='https://seekingalpha.com/symbol/ABC' title='AmerisourceBergen Corporation'>ABC</a>) (<font color='red'>-4%</font>) are feeling Cardinal's pain.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257545\" data-linked=\"Soft guidance sinks Cardinal; shares down 12% premarket\" data-tweet=\"$CAH $CAH $MCK - Soft guidance sinks Cardinal; shares down 12% premarket https://seekingalpha.com/news/3257545-soft-guidance-sinks-cardinal-shares-down-12-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3257545-soft-guidance-sinks-cardinal-shares-down-12-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257543\" data-ts=\"1492519001\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARNA\" target=\"_blank\">ARNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257543-arena-pharmaceuticals-prices-equity-offering-shares-slip-19-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arena Pharmaceuticals prices equity offering; shares slip 19% premarket</a></h4><ul> <li>Arena Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a>) slumps&nbsp;<font color='red'>19%</font>&nbsp;in response to the <a href=\"https://seekingalpha.com/pr/16801027-arena-pharmaceuticals-announces-pricing-public-offering-common-stock\" target=\"_blank\">pricing</a> of its public offering of 60M shares of common stock at $1.15 per share.</li><li>Underwriters over-allotment is an additional 9M shares.</li><li>Gross proceeds are $69M. Net proceeds will be used&nbsp;for clinical and preclinical development of drug candidates, for general corporate purposes, including working capital.</li><li>Closing date is &nbsp;April 21.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3257543\" data-linked=\"Arena Pharmaceuticals prices equity offering; shares slip 19% premarket\" data-tweet=\"$ARNA - Arena Pharmaceuticals prices equity offering; shares slip 19% premarket https://seekingalpha.com/news/3257543-arena-pharmaceuticals-prices-equity-offering-shares-slip-19-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3257543-arena-pharmaceuticals-prices-equity-offering-shares-slip-19-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257547\" data-ts=\"1492518964\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHP\" target=\"_blank\">BHP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257547-iron-oreminus-5-to-near-six-month-lows\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iron ore -5% to near six-month lows</a></h4><ul>     <li><a href=\"https://www.ft.com/content/bf62b812-241f-11e7-8691-d5f7e0cd0a16\" target=\"_blank\">The price of iron ore falls 5%</a> to a near six-month low, slammed by a decline in Chinese steel prices and concern about a supply glut.</li>     <li>Benchmark Australian ore for immediate delivery into China was down $3.10 to $61.50/metric ton, <em>Financial Times</em> reports, and has slumped by a third since hitting $94.50 two months ago, as steel production in China has <a href=\"https://seekingalpha.com/news/3257202-chinas-q1-gdp-growth-jumps-faster-expected-6_9-percent\" target=\"_blank\">continued to rise</a>.</li><li>&ldquo;We maintain a bearish view on iron ore,&rdquo; Citigroup analysts say, expecting prices to remain weak as an additional 70M-75M metric tons of supply from Australia, Brazil and India hits the market and demand growth in China slows.</li><li>In premarket trade: <a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color='red'>-2%</font>, <a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color='red'>-1.3%</font>, <a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a> <font color='red'>-2.8%</font>, <a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs, Inc.'>CLF</a> <font color='red'>-2%</font>.</li><li>Other relevant tickers: <a href='https://seekingalpha.com/symbol/AAUKF' title='Anglo American plc'>OTCQX:AAUKF</a>, <a href='https://seekingalpha.com/symbol/AAUKY' title='Anglo American plc ADR'>OTCPK:AAUKY</a>, <a href='https://seekingalpha.com/symbol/GLCNF' title='Glencore Plc'>OTCPK:GLCNF</a>, <a href='https://seekingalpha.com/symbol/GLNCY' title='Glencore Plc ADR'>OTCPK:GLNCY</a>, <a href='https://seekingalpha.com/symbol/FSUMF' title='Fortescue Metals Group Ltd'>OTCQX:FSUMF</a>, <a href='https://seekingalpha.com/symbol/ANFGF' title='Antofagasta plc'>OTC:ANFGF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3257547\" data-linked=\"Iron ore -5% to near six-month lows\" data-tweet=\"$BHP $BHP $RIO - Iron ore -5% to near six-month lows https://seekingalpha.com/news/3257547-iron-oreminus-5-to-near-six-month-lows?source=tweet\" data-url=\"https://seekingalpha.com/news/3257547-iron-oreminus-5-to-near-six-month-lows\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257539\" data-ts=\"1492518285\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLX\" target=\"_blank\">PLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257539-protalix-bios-prxminus-102-shows-encouraging-effect-in-fabry-models-compared-to-enzyme\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Protalix Bio&#39;s PRX-102 shows encouraging effect in Fabry models compared to enzyme replacement therapies; shares ahead 7% premarket</a></h4><ul><li>MIcro cap Protalix BioTherapeutics (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLX' title='Protalix BioTherapeutics, Inc'>PLX</a>) perks up&nbsp;<font color='green'>7%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16801278-protalix-biotherapeutics-announces-new-preclinical-results-demonstrating-positive-effect\" target=\"_blank\">announcement </a>of positive preclinical data on PRX-102 (pegunigalsidase alfa). In mouse models of Fabry disease, treatment with PRX-102 slowed the progression of small fiber neuropathy compared to mice treated with enzyme replacement therapy agalsidase alfa [Sanofi Genzyme's <a href=\"https://www.fabrazyme.com/\" target=\"_blank\">Fabrazyme</a>&nbsp;and Shire's <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000369/WC500053612.pdf\" target=\"_blank\">Replagal</a>].</li><li>Mice treated with PRX-102 showed a 53% reduction in Iba1 spots, a marker for inflammation of the peripheral nerves. There was no effect on Iba1 in mice treated with Fabrazyme or Replagal.</li><li>EVP, R&amp;D Dr.&nbsp;Yoseph Shaaltiel says, &ldquo;Significantly decreased Iba1 marker in treated Fabry mice suggests that repeated infusions of the drug from an asymptomatic stage prevents the activation and/or proliferation of resident DRG macrophages and alleviates damage to the peripheral sensory nerves. This change was not observed in Fabry mice treated with Fabrazyme or Replagal, an additional positive differentiation of pegunigalsidase alfa from currently approved therapies addressing Fabry disease neuropathy.&rdquo;</li><li><a href=\"http://www.protalix.com/development-pipeline/prx-102-fabry-disease.asp\" target=\"_blank\">PRX-102</a>&nbsp;is chemically modified version of a recombinant therapeutic enzyme called alpha-galactosidase A.</li><li><a href=\"https://ghr.nlm.nih.gov/condition/fabry-disease\" target=\"_blank\">Fabry disease</a>&nbsp;is an inherited disorder caused by mutations in the gene that codes for alpha-galactosidase A. It is characterized by the buildup of Gb3 in the body's cells.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257539\" data-linked=\"Protalix Bio&#39;s PRX-102 shows encouraging effect in Fabry models compared to enzyme replacement therapies; shares ahead 7% premarket\" data-tweet=\"$PLX - Protalix Bio&#39;s PRX-102 shows encouraging effect in Fabry models compared to enzyme replacement therapies; shares ahead 7% premarket https://seekingalpha.com/news/3257539-protalix-bios-prxminus-102-shows-encouraging-effect-in-fabry-models-compared-to-enzyme?source=tweet\" data-url=\"https://seekingalpha.com/news/3257539-protalix-bios-prxminus-102-shows-encouraging-effect-in-fabry-models-compared-to-enzyme\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257541\" data-ts=\"1492518274\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KATE\" target=\"_blank\">KATE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257541-sales-pressure-continues-for-kate-spade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sales pressure continues for Kate Spade</a></h4><ul> <li>Kate Spade (NYSE:<a href='https://seekingalpha.com/symbol/KATE' title='Kate Spade & Company'>KATE</a>) reports that direct-to-consumer comparable sales fell 2.4% in <a href=\"https://seekingalpha.com/pr/16801323-kate-spade-and-company-reports-first-quarter-2017-results\" target=\"_blank\">Q1</a>. The mark falls to -8.1% if the e-commerce channel is backed out.</li> <li>Kate Spade North America sales were down 0.6% during the quarter, while the international business was flat.</li><li>Gross profit as a percentage of sales increased 140 bps to 63.2%. SG&amp;A expenses came in at 60.7% of sales vs. 55.3% a year ago.</li> <li>Kate Spade ended the quarter with 448 stores vs. 452 a year ago.</li> <li>The company says that there is no definitive timeline for its review process. No new guidance was issued.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3257531-kate-spade-misses-0_06-misses-revenue\" target=\"_blank\">Kate Spade misses by $0.06, misses on revenue</a> (April 18)</li> <li>KATE <font color='red'>-2.06%</font> premarket to $19.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257541\" data-linked=\"Sales pressure continues for Kate Spade\" data-tweet=\"$KATE - Sales pressure continues for Kate Spade https://seekingalpha.com/news/3257541-sales-pressure-continues-for-kate-spade?source=tweet\" data-url=\"https://seekingalpha.com/news/3257541-sales-pressure-continues-for-kate-spade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257518\" data-ts=\"1492517955\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLPG\" target=\"_blank\">GLPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257518-galapagos-prices-338m-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galapagos prices $338M equity offering</a></h4><ul> <li>Galapagos NV (NASDAQ:<a href='https://seekingalpha.com/symbol/GLPG' title='Galapagos'>GLPG</a>) <a href=\"https://seekingalpha.com/pr/16801026-galapagos-raises-338-million-gross-proceeds-u-s-public-offering\" target=\"_blank\">prices&nbsp;</a>its U.S. public offering of 3.75M American Depositary Shares (ADSs) at $90 per ADS. Each ADS represents the right to receive one ordinary share. Gross proceeds should be $338M.</li>      <li>Underwriters over-allotment is an additional 562,500 ADSs. Closing date is April 21.</li>                     </ul><div class=\"tiny-share-widget\" data-id=\"3257518\" data-linked=\"Galapagos prices $338M equity offering\" data-tweet=\"$GLPG - Galapagos prices $338M equity offering https://seekingalpha.com/news/3257518-galapagos-prices-338m-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3257518-galapagos-prices-338m-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257535\" data-ts=\"1492517825\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GWW\" target=\"_blank\">GWW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257535-w-w-grainger-lowers-fy2017-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">W.W. Grainger lowers FY2017 guidance</a></h4><ul>     <li>W.W. Grainger (NYSE:<a href='https://seekingalpha.com/symbol/GWW' title='W.W. Grainger, Inc.'>GWW</a>) reports sales grew 1% in <a href=\"https://seekingalpha.com/pr/16801304-grainger-reports-results-2017-first-quarter\" target=\"_blank\">Q1</a>, driven by a 5&nbsp;percentage point increase from volume growth.</li>     <li>U.S. business sales down 1% to $1.95B.</li>     <li>Canada business sales grew 4% to $186.14M.</li>     <li>Other businesses sales rose 12% to $497.41M.</li>     <li>Gross margin rate down 160 bps to 40.1%</li>     <li>Adjusted operating margin rate squeezed 200 bps to 11.4%.</li>     <li><b>FY2017 Guidance</b>:&nbsp;Sales: +1% to +4%; Diluted EPS: $10 to $11.30; Tax rate: 35% to 36%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257535\" data-linked=\"W.W. Grainger lowers FY2017 guidance\" data-tweet=\"$GWW - W.W. Grainger lowers FY2017 guidance https://seekingalpha.com/news/3257535-w-w-grainger-lowers-fy2017-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3257535-w-w-grainger-lowers-fy2017-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257533\" data-ts=\"1492517263\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MITK\" target=\"_blank\">MITK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257533-mitekplus-4-on-new-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mitek +4% on new business</a></h4><ul><li>A global financial services outfit <a href=\"https://seekingalpha.com/pr/16801232-mitek-s-id-solutions-selected-global-financial-services-firm-improve-mobile-account-opening\" target=\"_blank\">has selected</a> Mitek's (NASDAQ:<a href='https://seekingalpha.com/symbol/MITK' title='Mitek Systems Inc.'>MITK</a>) Mobile Verify and Mobile Fill solutions to speed up and secure the mobile account opening process for its wealth management accounts.</li><li>Shares&nbsp;<font color='green'>+4.25%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3257533\" data-linked=\"Mitek +4% on new business\" data-tweet=\"$MITK - Mitek +4% on new business https://seekingalpha.com/news/3257533-mitekplus-4-on-new-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3257533-mitekplus-4-on-new-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257530\" data-ts=\"1492517032\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBT\" target=\"_blank\">GBT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257530-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Global Blood Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a>) initiated with Buy rating and $56 (93% upside) price target by SunTrust. Shares are up&nbsp;<font color='green'>3%</font>&nbsp;premarket.</li><li>Quotient (NASDAQ:<a href='https://seekingalpha.com/symbol/QTNT' title='Quotient Limited'>QTNT</a>) initiated with Buy rating and $22 (251% upside) price target by BTIG Research.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257530\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$GBT $GBT $QTNT - Premarket analyst action - healthcare https://seekingalpha.com/news/3257530-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3257530-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257527\" data-ts=\"1492516940\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GS\" target=\"_blank\">GS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257527-goldman-sees-no-trading-revenue-bump-in-q1-shares-down-3_65-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman sees no trading revenue bump in Q1; shares down 3.65% premarket</a></h4><ul><li>Q1 net income of $2.162B or $5.15 per share vs. $1.2B and $2.68 one year ago.</li><li>Investment Banking revenues of $1.7B up 16% Y/Y; advisory revenue of $756M down 2%; underwriting revenue of $947M up 37%. Investment banking backlog slipped from Q4 and from a year ago.</li><li>Institutional Client Services revenue of $3.36B down 2% Y/Y. FICC revenue of $1.69B flat from a year ago. Equities revenue of $1.67B down 6%.</li><li>Investment &amp; Lending revenue of $1.46B up sharply from a year ago.</li><li>Investment Management revenue of $1.5B up 12% Y/Y.</li><li>Compensation and benefits of $3.29B up 24% Y/Y. Ratio of comp and benefits to revenue unchanged at 41%.</li><li>Standard CET1 ratio of 14.2%; advanced of 12.9%. Quarterly dividend is boosted to $0.75 from $0.65. Tangible book value per share of $175.05.</li><li>6.2M shares bought back during quarter at average cost of $243.22 each. Another 50M of buybacks is authorized.</li><li><a href=\"http://www.goldmansachs.com/investor-relations\" target=\"_blank\">Conference call at 9:30 ET</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3257516-goldman-sachs-misses-0_02-misses-revenue\" target=\"_blank\">Goldman Sachs misses by $0.02, misses on revenue</a> (April 18)</li><li><a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a>&nbsp;<font color='red'>-3.65%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3257527\" data-linked=\"Goldman sees no trading revenue bump in Q1; shares down 3.65% premarket\" data-tweet=\"$GS - Goldman sees no trading revenue bump in Q1; shares down 3.65% premarket https://seekingalpha.com/news/3257527-goldman-sees-no-trading-revenue-bump-in-q1-shares-down-3_65-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3257527-goldman-sees-no-trading-revenue-bump-in-q1-shares-down-3_65-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257519\" data-ts=\"1492516300\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HOG\" target=\"_blank\">HOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257519-u-s-sales-weak-for-harley-davidson\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. sales weak for Harley-Davidson</a></h4><ul>     <li>Harley-Davidson (NYSE:<a href='https://seekingalpha.com/symbol/HOG' title='Harley-Davidson, Inc.'>HOG</a>) reports motorcycle shipments fell 14.7% Y/Y to 70,831 in <a href=\"https://seekingalpha.com/pr/16801176-harley-davidson-releases-first-quarter-2017-results\" target=\"_blank\">Q1</a>.</li>     <li>U.S. retail motorcycles were down 5.7% to miss the expectation of analysts. Harley's U.S. market share in the 601cc-plus segment was up to 51.3%.</li>     <li>International sales fell 1.8%, driven lower by a 9% drop in the Asia Pacific region.</li>     <li>Operating margin in the motorycle segment fell 310 bps to 18.0%.</li>     <li>The company is taking the approach of holding back some 2017 models in order to help U.S. dealers clear out 2016 inventory.    =</li><li>Looking ahead, Harley expects 2017 shipments to be flat to down modestly compared to last year. Q2 shipments of 80K to 85K are anticipated.</li>         <li>Previously: <a href=\"https://seekingalpha.com/news/3257497-harley-davidson-beats-0_03-misses-revenue\" target=\"_blank\">Harley-Davidson beats by $0.03, misses on revenue</a> (April 18)</li>         <li>HOG <font color='red'>-4.12%</font> premarket to $56.95.</li>    ==</ul><div class=\"tiny-share-widget\" data-id=\"3257519\" data-linked=\"U.S. sales weak for Harley-Davidson\" data-tweet=\"$HOG - U.S. sales weak for Harley-Davidson https://seekingalpha.com/news/3257519-u-s-sales-weak-for-harley-davidson?source=tweet\" data-url=\"https://seekingalpha.com/news/3257519-u-s-sales-weak-for-harley-davidson\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257506\" data-ts=\"1492514611\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNH\" target=\"_blank\">UNH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257506-unitedhealth-q1-revenues-up-9-non-gaap-eps-up-31-updates-2017-guidance-shares-up-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UnitedHealth Q1 revenues up 9%; non-GAAP EPS up 31%; updates 2017 guidance; shares up 2% premarket</a></h4><ul><li>UnitedHealth Group (<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a> <font color='green'>+1.3%</font>) <a href=\"https://seekingalpha.com/pr/16801112-unitedhealth-group-first-quarter-highlights\" target=\"_blank\">Q1 results</a>: Revenues: $48,723M (+9.4%); Premiums: $38,938M (+11.9%); Products: $6,129M (-4.1%); Services: $3,434M (+9.4%); Investment and other income: $222M (+21.3%); Net Income: $1M (0.0%); EPS: $1 (0.0%); Non-GAAP EPS: $1 (0.0%); Quick Assets: $1M (0.0%); CF Ops: $1M (0.0%).</li><li>UnitedHealthcare: $40,136M (+11.8%); Optum: $21,237M (+7.9%).</li><li>Employer &amp; Individual Revenues: $12,739M (-0.6%); Medicare &amp; Retirement Revenues: $16,552M (+17.7%); Community &amp; State Revenues: $8,949M (+15.8%); Global Revenues: $1,896M (+47.3%);</li><li>OptumHealth: $4,733M (+18.4%); OptumInsight: $1,843M (+10.6%); OptumRx: $1,4947M (+4.7%).</li><li>Operating Income: $3,413M (+15.3%); Net Income: $2,172M (+34.8%); EPS: $2.23 (+33.5%); Non-GAAP EPS: $2.37 (+30.9%); Quick Assets: $19,352M (+45.8%); CF Ops: $6,456M (+178.5%).</li><li><strong>2017 Guidance</strong>: Revenues: ~$200B; GAAP EPS: $9.10 - $9.30; Non-GAAP EPS: $9.65 - 9.85; CF Ops: ~$12B.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257506\" data-linked=\"UnitedHealth Q1 revenues up 9%; non-GAAP EPS up 31%; updates 2017 guidance; shares up 2% premarket\" data-tweet=\"$UNH - UnitedHealth Q1 revenues up 9%; non-GAAP EPS up 31%; updates 2017 guidance; shares up 2% premarket https://seekingalpha.com/news/3257506-unitedhealth-q1-revenues-up-9-non-gaap-eps-up-31-updates-2017-guidance-shares-up-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3257506-unitedhealth-q1-revenues-up-9-non-gaap-eps-up-31-updates-2017-guidance-shares-up-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257503\" data-ts=\"1492514293\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAH\" target=\"_blank\">CAH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257503-cardinal-health-buys-three-businesses-from-medtronic-for-6_1b-shares-down-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cardinal Health buys three businesses from Medtronic for $6.1B; shares down 7% premarket</a></h4><ul><li>Cardinal Health (NYSE:<a href='https://seekingalpha.com/symbol/CAH' title='Cardinal Health Inc.'>CAH</a>) inks an <a href=\"https://seekingalpha.com/pr/16801175-cardinal-health-acquire-leading-patient-product-portfolio-medtronic-6_1-billion\" target=\"_blank\">agreement</a> with Medtronic (NYSE:<a href='https://seekingalpha.com/symbol/MDT' title='Medtronic plc'>MDT</a>) to acquire its Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses for $6.1B. Total revenues of the three units were $2.3B for the 12-month period ending October 2016.</li><li>The deal will be immediately accretive by more than $0.21 to fiscal 2018 non-GAAP EPS, including $100M of inventory step-up costs during the first several quarters, and $0.55 to non-GAAP EPS in fiscal 2019. By the end of 2020, synergies will exceed $150M/year. Cardinal will add more than 10K employees to the payroll.</li><li>The transaction will be financed with cash on hand and $4.5B in new senior unsecured debt.</li><li>Chairman and CEO George S. Barrett says, \"We are thrilled about today's announcement, as this well-established product line is complementary to our medical consumables business and fits naturally into our customer offering. For this reason, this product portfolio has been on our radar for many years. We distribute some of these products today and have been collaborative partners with the leadership of this business. Given the current trends in healthcare, including aging demographics and a focus on post-acute care, this industry-leading portfolio will help us further expand our scope in the operating room, in long-term care facilities and in home healthcare, reaching customers across the entire continuum of care.\"</li><li>CAH is down&nbsp;<font color='red'>7%</font>&nbsp;and MDT is up&nbsp;<font color='green'>1%</font>&nbsp;premarket, both on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3257503\" data-linked=\"Cardinal Health buys three businesses from Medtronic for $6.1B; shares down 7% premarket\" data-tweet=\"$CAH $CAH $MDT - Cardinal Health buys three businesses from Medtronic for $6.1B; shares down 7% premarket https://seekingalpha.com/news/3257503-cardinal-health-buys-three-businesses-from-medtronic-for-6_1b-shares-down-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3257503-cardinal-health-buys-three-businesses-from-medtronic-for-6_1b-shares-down-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257505\" data-ts=\"1492514235\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAC\" target=\"_blank\">BAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257505-surge-in-trading-revenue-boosts-bofas-quarter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Surge in trading revenue boosts BofA&#39;s quarter</a></h4><ul><li>Q1 net income of $4.9B or $0.41 per share vs. $3.5B and $0.28 earned one year ago.</li><li>Consumer Banking net income of $1.89B up 7% Y/Y. Net interest income of $5.78B up 8.5%; deposit balances up 10%. Noninterest income of $2.5B slipped a hair mostly thanks to lower mortgage banking income and a divestiture gain recorded in Q1 a year ago. Provisions for credit losses of $838M vs. $531M a year ago; reserve build this year of $66M vs. a $208M release a year ago. Efficiency ratio improves to 53% from 58%.</li><li>Global Wealth and Investment Management net income of $770M up 4% Y/Y.</li><li>Global Banking net income of $1.729B up 58% Y/Y. Provisions for credit losses fell to just $17M from $536M thanks to energy improvement. Investment banking fees up 37% to $1.6B.</li><li>Global Markets net income of $1.297B up 33% Y/Y, with revenue up 27%. Sales and trading revenue of $4B up 23%; FICC revenue up 29%.</li><li><a href=\"http://investor.bankofamerica.com\" target=\"_blank\">Conference call</a> at 8:30 ET</li><li>Previously: <a href=\"https://seekingalpha.com/news/3257495-bank-america-beats-0_06-beats-revenue\" target=\"_blank\">Bank of America beats by $0.06, beats on revenue</a> (April 18)</li><li><a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a>&nbsp;<font color='green'>+1.3%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3257505\" data-linked=\"Surge in trading revenue boosts BofA&#39;s quarter\" data-tweet=\"$BAC - Surge in trading revenue boosts BofA&#39;s quarter https://seekingalpha.com/news/3257505-surge-in-trading-revenue-boosts-bofas-quarter?source=tweet\" data-url=\"https://seekingalpha.com/news/3257505-surge-in-trading-revenue-boosts-bofas-quarter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3257502\" data-ts=\"1492514070\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNC\" target=\"_blank\">GNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257502-gnc-holdings-spikes-after-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GNC Holdings spikes after earnings beat</a></h4><ul> <li>GNC Holdings (NYSE:<a href='https://seekingalpha.com/symbol/GNC' title='GNC Holdings, Inc.'>GNC</a>) reports a 3.9% decrease in same-store sales for <a href=\"https://seekingalpha.com/pr/16801172-gnc-holdings-inc-reports-first-quarter-2017-results\" target=\"_blank\">Q1</a> to top the consensus analyst expectation for a 8% drop. Same-store sales were down 4.6% in franchised U.S. stores.</li> <li>Transaction growth was up 9.3% during the quarter, while average transaction amount fell 12.1%.</li> <li>Sales off the website channel fell 7.2% due in part to a pricing adjustment, but management says the GNC storefront on Amazon is topping expectations.</li> <li>Revenue fell 3.8% in the U.S. and Canada segment to $553M during the quarter. International segment revenue was up 7% to $39.4M. Manufacturing/wholesale revenue fell 8.6% to $53M.</li> <li>The company ended the quarter with a total of 8,983 store locations globally vs. 9,064 stores a year ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3257494-gnc-holdings-beats-0_03-beats-revenue\" target=\"_blank\">GNC Holdings beats by $0.03, beats on revenue</a> (April 18)</li> <li>GNC <font color='green'>+36.74%</font> premarket to $9.90.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3257502\" data-linked=\"GNC Holdings spikes after earnings beat\" data-tweet=\"$GNC - GNC Holdings spikes after earnings beat https://seekingalpha.com/news/3257502-gnc-holdings-spikes-after-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3257502-gnc-holdings-spikes-after-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}